https://www.pharmaradar360.com hourly 1 https://www.pharmaradar360.com/news hourly 0.95 https://www.pharmaradar360.com/regulators daily 0.9 https://www.pharmaradar360.com/trials daily 0.85 https://www.pharmaradar360.com/pipeline daily 0.9 https://www.pharmaradar360.com/drug-approvals daily 0.9 https://www.pharmaradar360.com/journals weekly 0.8 https://www.pharmaradar360.com/pharma-companies weekly 0.8 https://www.pharmaradar360.com/specialties weekly 0.8 https://www.pharmaradar360.com/sources weekly 0.8 https://www.pharmaradar360.com/newsrooms weekly 0.8 https://www.pharmaradar360.com/pharma-tools weekly 0.8 https://www.pharmaradar360.com/pharma-communities weekly 0.75 https://www.pharmaradar360.com/pro weekly 0.75 https://www.pharmaradar360.com/tools weekly 0.7 https://www.pharmaradar360.com/about monthly 0.5 https://www.pharmaradar360.com/privacy yearly 0.35 https://www.pharmaradar360.com/support monthly 0.35 https://www.pharmaradar360.com/disclaimer yearly 0.35 https://www.pharmaradar360.com/drug/pembrolizumab daily 0.9 https://www.pharmaradar360.com/drug/semaglutide daily 0.9 https://www.pharmaradar360.com/drug/tirzepatide daily 0.9 https://www.pharmaradar360.com/drug/trastuzumab-deruxtecan daily 0.9 https://www.pharmaradar360.com/drug/osimertinib daily 0.9 https://www.pharmaradar360.com/drug/nivolumab daily 0.9 https://www.pharmaradar360.com/drug/dupilumab daily 0.9 https://www.pharmaradar360.com/drug/risankizumab daily 0.9 https://www.pharmaradar360.com/drug/lecanemab daily 0.9 https://www.pharmaradar360.com/drug/atezolizumab daily 0.9 https://www.pharmaradar360.com/article/veraxa-biotech-vrxa-insider-trading-activity-2026-249623a1453a3bf2 2026-09-13T10:28:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/india-s-patent-office-issues-draft-guidelines-for-pharma-biotech-patents-f5ea25ff845c0d58 2026-09-13T10:20:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/kardigan-funded-precision-cardiology-offers-more-than-pipeline-diversification-903862474345a45e 2026-09-13T10:10:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-breakthrough-cancer-vaccine-fueled-a-biotech-rally-can-it-last-16c0e73db8d97a9a 2026-09-13T10:08:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/scientist-challenges-pharmaceutical-ceo-7d668b086603b6da 2026-09-13T09:34:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/mirum-s-azure-3-trial-a-new-switch-strategy-in-chronic-hepatitis-d-7e2f82ccd93e8fa1 2026-09-13T09:17:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmacists-and-civic-groups-in-south-korea-rally-to-block-telemedicine-drug-del-b3f335563b1d4740 2026-09-13T08:37:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/kush-choksi-promoted-to-assistant-vice-president-business-development-at-strides-67d859a68cdf70fc 2026-09-13T08:25:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/russians-attack-ukraine-s-second-largest-pharmaceutical-warehouse-twice-e64594d4abfd7904 2026-09-13T08:13:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/merali-family-acquires-stake-in-sh330-million-mombasa-glass-plant-534ff22c2cb25d15 2026-09-13T08:06:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/california-state-teachers-retirement-system-grows-holdings-in-teva-pharmaceutica-401670e366181271 2026-09-13T08:06:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/indian-patent-office-releases-draft-pharma-and-biotech-patent-rules-745c2dc8449c8b47 2026-09-13T08:04:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/ris-rez-reduced-risk-of-death-by-54-versus-topotecan-in-patients-with-relapsed-s-bc1325534320d150 2026-09-13T08:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/mitapivat-just-rewrote-the-treatment-floor-for-transfusion-dependent-thalassaemi-0e1aeb228fea5f5f 2026-09-13T07:28:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/indian-patent-office-proposes-new-guidelines-for-pharma-patent-examination-458c5763c48de19f 2026-09-13T07:21:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/tam-peli-meets-primary-endpoint-for-relapsed-small-cell-lung-cancer-in-phase-iii-ac7af87a08f589ad 2026-09-13T06:38:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/iza-bren-2-5-mg-kg-dose-advances-to-phase-3-in-egfr-mutated-nsclc-70789e99d842e835 2026-09-13T06:38:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/j-j-exits-laa-closure-market-sells-laminar-program-to-jaguar-laa-77731cf65f918dd3 2026-09-13T06:38:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/antibody-drug-combination-falls-short-in-first-line-pd-l1-high-metastatic-lung-c-355a95d6d905ce35 2026-09-13T04:02:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/holiferm-and-organica-uk-combine-to-build-integrated-biotech-and-sustainable-pro-326ddd6adcb0a06e 2026-09-13T02:17:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/aan-ahs-issue-updated-guideline-on-migraine-prevention-atogepant-meets-end-point-fba9ebb04f21030b 2026-09-13T01:48:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/bhushan-malpure-elevated-to-head-of-marketing-at-cipla-9e97a17d55f1f388 2026-09-13T01:26:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/polyester-thermal-ribbon-material-market-forecast-to-2035-driven-by-coding-and-m-423a025c3eff05f6 2026-09-13T00:41:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/sls-stock-hits-over-3-year-high-as-aml-drug-trial-nears-final-readout-wall-stree-d690b1c596b74875 2026-09-13T00:37:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/roche-s-cancer-drug-cut-death-risk-54-in-a-phase-iii-trial-aa806bf235967344 2026-09-13T00:13:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/roche-s-collaborator-medilink-announces-phase-iii-data-for-tam-peli-showing-sign-59cd66eaa83f33ab 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-41783f9f4fe26fa5 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-8a1d864a54a236f9 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-a1f50862dd647aed 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-cf79c90c168f6560 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-fca71bb67ffc6cf4 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-016ed0daa4a382fa 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-90999b8b729a522f 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-156eee7f0569b172 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-e666d6c5cf38bd2f 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-6419ab92143f43ec 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-bcdfd5f502ec0627 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-164ee15f02b3d2e2 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-fe6ef9fbd454d7d9 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/home-page-853c14e9c637dcb2 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/integrated-clinical-biological-and-echocardiographic-factors-independently-assoc-d9399d45b2a33f73 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/an-interpretable-machine-learning-technique-for-chronic-kidney-disease-diagnosis-a36eb0bcde8fec07 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hemodynamic-assessment-of-different-septic-shock-resuscitation-strategies-a-comp-2e608c74e044dc35 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/lt-b-gt-daily-versus-thrice-weekly-antituberculosis-therapy-for-drug-susceptible-0c5ecbecd8d647ea 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/phenotypic-biofilm-formation-and-detection-of-biofilm-associated-genes-in-multid-36922277a1ca5ce2 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/metabolic-consequences-of-vitamin-b6-deficiency-and-their-impact-on-lipid-metabo-27d51c561cbb492d 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluating-public-acceptance-of-the-official-medicine-label-and-mobile-verificat-5ced3fb490225291 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/global-in-vitro-antimicrobial-susceptibility-profiles-of-mycobacterium-abscessus-fa989aa6b0f056d5 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/determinants-of-adverse-drug-reaction-reporting-for-antimalarial-medicines-a-mix-7f511f27b1f61e6c 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pre-surgical-immune-proteomic-profiles-in-serum-identify-inflamed-and-suppressed-4dc9fd98b8b9ad71 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bibliometric-analysis-of-clinical-trials-on-tobacco-use-and-mental-health-resear-6825e6a1bf36f0a8 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-and-implementation-of-a-multi-attribute-quality-robustness-scoring-f-d6af0f220fb3e1dd 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-impact-of-undiagnosed-child-adhd-on-family-outcomes-e35f9938b3a191a5 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/meaning-centered-psychotherapy-for-existential-distress-and-demoralization-in-ad-0771ba15c32a9d1b 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/establishing-non-fasting-lipid-reference-intervals-and-clinical-decision-limits-f81e8304eb1fab70 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/exploring-the-interplay-between-interoception-and-dissociative-experiences-insig-6419b2b230094dd4 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/influence-of-gingival-thickness-on-clinical-outcomes-following-surgical-scalpel-1c459f18acc6a61b 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-usability-of-an-explainable-ai-decision-support-tool-and-evaluation-of-f5c3a6def263501a 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-efficacy-and-safety-of-celecoxib-for-postoperative-pain-in-major-orthopedic-c41f40b2e490fa69 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/age-dependent-performance-of-conventional-trauma-scores-in-older-trauma-patients-df5cb966635b6338 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/real-world-effectiveness-of-telitacicept-in-ebv-seropositive-patients-with-syste-fe93f7a17f0003a4 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/multimodal-analysis-of-dental-radiographs-and-clinical-data-for-cardiovascular-r-13110790ce722d04 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/construction-of-a-large-scale-biomedical-corpus-for-nlp-based-clinical-evidence-66d27e28a834d045 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gc-biopharma-gets-phase-2-approval-for-covid-19-vaccine-bfab50deecd04760 2026-09-12T23:26:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/samsung-bioepis-named-top-job-creating-company-eb946f6413a4e87a 2026-09-12T23:26:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/veraxa-biotech-ag-stock-price-vrxa-stock-chart-market-cap-news-today-4961193ae7b32abd 2026-09-12T22:56:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/eli-lilly-makes-another-biotech-bet-ahead-of-retatrutide-data-lly-stock-surges-t-f277b743c44c8524 2026-09-12T22:18:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/adio-signs-strategic-deal-with-german-biotech-company-bayer-ac2bbec6d7c144ab 2026-09-12T22:02:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/germantown-s-seraxis-announces-merger-to-form-diabetes-focused-biotech-company-040970b898a6533a 2026-09-12T22:00:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/danish-pharmaceutical-novo-nordisk-introduces-ozempic-wegovy-drugs-in-kenya-eea7db5abbecd051 2026-09-12T21:12:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/medpacto-trials-revive-deal-prospects-as-theragen-etex-weighs-holding-stake-chos-d0c51f66ec7b502d 2026-09-12T21:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cancer-drug-hand-foot-syndrome-risks-mapped-in-huge-fda-analysis-238ae56f04af0703 2026-09-12T20:58:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-speakers-the-complete-guide-to-find-book-hire-a-keynote-for-corpo-8a1ec198d20550d6 2026-09-12T20:33:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-supply-chains-urged-to-begin-ndc-12-transition-planning-immediate-6e46cc9019edde23 2026-09-12T20:30:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/trial-setback-might-change-the-case-for-investing-in-ultragenyx-stock-rare-3e2680d41502b831 2026-09-12T19:29:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-your-ndc-12-roadmap-should-start-now-01536b53d86921d0 2026-09-12T19:29:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/cms-s-hemp-cbd-program-has-a-physician-problem-mmj-appeal-pending-44ea6724fd164998 2026-09-12T19:23:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/donald-trump-talked-about-a-united-ireland-in-dublin-not-the-september-29-pharma-471e8e5510cb1b5f 2026-09-12T19:07:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/china-s-plan-to-leap-ahead-in-race-for-next-big-weight-loss-drug-f45ef54de9ee97d7 2026-09-12T19:04:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-cdc-confirm-cyclosporiasis-outbreak-linked-to-taylor-farms-lettuce-under-con-c3bf319fa3d66a29 2026-09-12T18:02:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-direxion-daily-pharmaceutical-medical-bull-3x-shares-pill-affects-rotational-37342cd9f0425108 2026-09-12T18:02:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/rfk-jr-says-fda-will-act-on-petition-to-reexamine-some-ingredients-in-ultra-proc-612c000bde7480b5 2026-09-12T17:46:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/mbrx-stock-drops-25-as-moleculin-biotech-s-interim-cancer-trial-data-falls-short-d8f025f87aa6b36f 2026-09-12T17:12:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/cathie-wood-s-biotech-bet-intellia-secured-an-fda-priority-review-for-rare-genet-5f7c852de259bb0e 2026-09-12T17:11:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/etfs-investing-in-cabio-biotech-wuhan-co-ltd-class-a-stocks-a33d8632bf3d3697 2026-09-12T17:07:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/ai-cyber-outer-space-biotech-critical-tech-shaping-opportunities-of-future-cbcbdcf9f3438d5c 2026-09-12T16:40:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/sls-ibrx-eye-green-month-as-biotech-etf-gains-steam-analyst-sees-continued-oppor-6a1aa66cf3396998 2026-09-12T16:40:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/promising-biotech-stocks-to-keep-an-eye-on-september-12th-efe64c7ece99109b 2026-09-12T16:07:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/perioperative-immunotherapy-more-than-doubles-event-free-survival-in-early-stage-583f131177b9b417 2026-09-12T16:07:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-stocks-need-a-shot-in-the-arm-after-brutal-july-could-astrazeneca-bristo-0c28c1010a46e800 2026-09-12T14:36:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/an-officer-may-come-and-go-but-a-trustworthy-institution-must-endure-says-tukara-a4fd43de647a7b40 2026-09-12T14:30:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/this-small-cap-biotech-is-having-its-best-week-in-a-month-here-s-what-s-driving-681ea6d29eda7205 2026-09-12T14:26:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/strata-mental-health-solutions-receives-compass-pathways-grant-for-comp360-provi-5e7e3f29061c4e4e 2026-09-12T13:56:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/can-fite-publishes-peer-reviewed-article-on-piclidenoson-and-namodenoson-potenti-0af5a6d68d575775 2026-09-12T13:47:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/trump-drug-pricing-deals-and-policy-uncertainty-create-unreadable-market-landsca-049be17091ba1587 2026-09-12T13:36:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/fundly-ai-raises-4-9-million-to-expand-b2b-pharma-platform-c50ea0daee21a08b 2026-09-12T13:14:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/technical-analysis-of-state-street-spdr-s-p-biotech-etf-cryptocom-xbiusd-p-251011cd265c51ab 2026-09-12T13:06:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/afghan-indian-officials-discuss-pharmaceutical-cooperation-b51c7c0a0b565719 2026-09-12T13:01:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/evotec-stock-holds-near-52-week-low-as-revenue-drops-in-first-half-cef31d0bcd8eed64 2026-09-12T12:59:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/b2b-pharma-platform-fundly-ai-raises-4-million-to-expand-commerce-payments-and-c-c143e24ddef24c12 2026-09-12T12:54:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-s-atogepant-delivers-positive-phase-3-results-in-menstrual-migraine-9b5b3859971b5d2e 2026-09-12T12:30:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/should-debt-refinance-require-action-from-teva-teva-investors-85e0988c5562c871 2026-09-12T12:26:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/uzbekistan-health-agency-partex-ai-to-develop-digital-solutions-9f48d894eef80e20 2026-09-12T12:15:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/india-joint-venture-partners-to-manufacture-pharmaceutical-products-in-moscow-ka-dc137a5820db4ea6 2026-09-12T12:03:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/phase-1-study-supports-recommended-phase-3-dose-for-investigational-egfr-x-her3-9b4c556986e84b1d 2026-09-12T11:41:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/uzbekistan-presents-pharmaceutical-products-in-south-korea-b84311811128667d 2026-09-12T11:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/astrazeneca-s-breast-cancer-drug-etcamah-fails-serena-4-trial-4c465fc11872fde1 2026-09-12T11:16:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/zhu-baoguo-founder-of-taitai-oral-liquid-steps-down-as-chairman-of-two-chinese-l-33a6de160dc6d765 2026-09-12T10:35:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/azerbaijan-s-pharmaceutical-spending-rises-nearly-22-42364ddbd6b7dcf1 2026-09-12T10:32:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/eu-court-adviser-backs-challenge-to-pharmaceutical-wastewater-charges-f5177be301b558f1 2026-09-12T09:38:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/mesoblast-completes-phase-3-trial-dosing-for-chronic-back-pain-therapy-663a24f4517ade40 2026-09-12T09:09:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/cyprus-tip-off-led-to-greek-raid-on-illegal-drug-laboratory-linked-to-mazonakis-5f9d99378c2c09f4 2026-09-12T09:04:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/100-million-investment-plan-clears-way-for-bigger-pivot-park-176bf58aa84aed4b 2026-09-12T08:55:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/advanced-breast-cancer-drug-fails-key-clinical-trial-days-after-regulatory-appro-098d437bd645687d 2026-09-12T08:50:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-pension-service-acquires-112-357-shares-of-teva-pharmaceutical-industri-260337801488a062 2026-09-12T08:37:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/is-west-pharmaceutical-services-wst-cheap-following-its-recent-run-up-9d80bd8465e3c4d8 2026-09-12T08:23:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparing-healthcare-etfs-broad-vs-focused-exposure-516ea007c530dc21 2026-09-12T08:13:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/relmada-s-ndv-01-bladder-cancer-trial-moves-into-phase-3-what-investors-should-w-6ae6a2ee7fa3d97e 2026-09-12T08:00:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/pakistan-pharma-industry-medicine-prices-drug-supply-pharmaceutical-policy-aaj-n-12b516d606ae7852 2026-09-12T07:00:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/pakistan-pharma-industry-medicine-prices-drug-supply-pharmaceutical-policy-aaj-n-ef0a623ac1e73cec 2026-09-12T07:00:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-raids-11-thane-farsan-manufacturers-seizes-food-stock-worth-20-48-lakh-b5b76e392e3e4591 2026-09-12T06:57:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/top-14-pharma-stocks-to-buy-in-india-september-2026-1ca08eb69cc1f994 2026-09-12T06:51:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/jpmorgan-initiates-dianthus-stock-at-overweight-135-target-by-investing-com-eeff66b407baecfd 2026-09-12T06:49:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/china-accepts-ncx-470-nda-for-review-in-glaucoma-treatment-cfc222df1edb77f1 2026-09-12T06:44:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/pune-fda-registration-mandatory-for-ganesh-mandals-distributing-prasad-fb8b05dd2f28ecd1 2026-09-12T06:36:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/thai-fda-reports-over-52m-baht-peptide-haul-on-september-11-a6e10730598338f8 2026-09-12T06:21:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/dftx-vs-cmps-which-stock-has-more-upside-from-trump-s-new-psychedelic-therapy-pu-ef64dcf5e3960581 2026-09-12T06:05:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/south-korea-s-drug-agency-lags-behind-1960s-fda-d3716d4263c37159 2026-09-12T04:52:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/cmps-stock-clocks-muted-gains-but-analysts-back-psychedelic-drug-s-durability-ah-6a4a3cae17e5d82c 2026-09-12T04:28:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/frost-sullivan-presents-the-global-gene-therapy-crdmo-technology-innovation-lead-a3f7024e958c3afe 2026-09-12T04:25:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/acquired-hemophilia-a-clinical-trial-pipeline-gains-momentum-c128454433b644e0 2026-09-12T04:18:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/vietnam-vaccine-joint-stock-company-d68bb00762a34154 2026-09-12T04:17:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/tracing-and-technology-at-the-food-and-drug-administration-fbfa4ab87a9c4f5c 2026-09-12T04:09:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-faces-a-reckoning-three-trial-failures-in-eight-days-test-the-limits-of-f4e0f13966bf3133 2026-09-12T03:50:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/suspect-escapes-after-pursuit-following-drug-use-call-at-sequim-longhouse-6127b7b4572c5641 2026-09-12T03:38:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/lady-gaga-and-michael-polansky-found-ai-biotech-company-77cc0d4530cd162b 2026-09-12T03:33:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/k-bio-firms-make-trillion-won-bets-to-secure-overseas-new-drugs-jkn-8615c51b08db3bfa 2026-09-12T03:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/india-should-be-an-ai-powered-innovation-hub-and-not-just-a-low-cost-hub-dr-mahe-4c8e80ec418106a5 2026-09-12T03:29:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/pune-fda-seizes-paneer-from-four-trucks-in-budhwar-peth-ahead-of-ganeshotsav-cel-e9086992498407f7 2026-09-12T03:04:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/journal-of-pharmaceutical-investigation-records-strong-citation-growth-with-5-5-690954f81d3094bf 2026-09-12T03:01:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbv-stock-gains-on-winning-fda-approval-for-rare-blood-cancer-drug-1cabfd1aed67f747 2026-09-12T02:21:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/genscript-biotech-1548-hk-synthetic-expert-call-transcript-11-sep-2026-de67dd4d07cf5638 2026-09-12T02:19:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-company-expanding-adding-jobs-in-hauppauge-d80f5da0a5cd0868 2026-09-12T02:18:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/hoth-s-pivot-from-biotech-to-space-tech-sparks-massive-rally-in-stock-retail-und-fea1a8d486dec34b 2026-09-12T01:58:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/burning-rock-biotech-bnr-stock-rallies-while-losses-still-deepen-6fa40a99877d8199 2026-09-12T01:32:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/sls-stock-snaps-2-day-slide-sellas-sls009-aml-trial-spotlights-big-pharma-drug-c-f36c0d0b6d235967 2026-09-12T01:29:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-startups-qualify-for-r-d-tax-credits-more-often-than-they-realize-k-38-c-99f5d2da9c4c0918 2026-09-12T01:20:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/lilly-completes-ataibeckley-deal-adding-investigational-depression-pipeline-21206a1893121249 2026-09-12T01:00:53.000Z weekly 0.7 https://www.pharmaradar360.com/article/biomarin-pharmaceutical-bmrn-posts-phase-3-win-and-fda-filing-in-hypochondroplas-ddd070aa04ad5d21 2026-09-12T00:52:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/new-bill-seeks-to-fix-drug-preclusion-provision-to-boost-dietary-supplement-inno-4a7fbbe7147f63f6 2026-09-12T00:04:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/correlation-between-peak-expiratory-flow-rate-and-single-breath-count-in-patient-44cbb583fbb6fbdd 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/angina-bullosa-hemorrhagica-of-the-buccal-mucosa-a-diagnostic-challenge-in-an-or-c499811e3eb18f87 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/oral-myiasis-a-structured-review-of-risk-factors-clinical-presentation-and-treat-a135c68806420554 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/vitamin-d-dependent-rickets-type-1a-recognizing-clinical-clues-to-avoid-delayed-98e6b364df2a9e62 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-lightweight-hybrid-cnn-transformer-model-for-early-retinal-disease-screening-i-ebb3e4a15bbb9858 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biblical-solutions-to-depression-a-critical-theological-pastoral-and-clinical-ex-769d167106a170c8 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/key-contamination-control-trends-identified-in-recent-fda-warning-letters-ec206a6030b88158 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bactifind-an-offline-first-mobile-application-integrating-multiple-diagnostic-an-a90360d7fb045a26 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluating-lstm-neural-networks-with-moving-average-features-for-short-term-stoc-2126b75c8d06bfc9 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/peer-review-report-for-improving-measurement-and-priorities-for-assessment-in-cl-0b36c70adde672df 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/phenotype-detection-of-biofilm-from-serratia-and-staphylococcus-aureus-isolated-e177cef720d9a902 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/147092de57e5fedc 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-public-health-and-clinical-workers-thought-about-climate-change-related-heal-db145f0e4a3b5085 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-anatomical-profile-of-patients-undergoing-cryoballoon-left-common-p-ba1b007a5bfe8cb3 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-analysis-of-the-cytokine-and-adipokine-profile-and-their-association-fce51a280cd65e62 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/preparation-of-highly-functionalized-lt-i-gt-ortho-lt-i-gt-naphthoquinone-methid-95395027a0c57261 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/highly-efficient-cellular-uptake-and-membrane-permeability-of-cell-penetrating-p-93591645586f0f0d 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-machine-learning-based-clinical-decision-support-system-developed-using-the-ni-dc6299db2e41b493 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effects-of-combined-exercise-training-and-bicycle-ergonomic-adaptation-on-cyclin-9b7295e862750c9a 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/transcriptomic-profiling-of-paired-clinical-leishmania-mundinia-martiniquensis-i-b36bf486134862d1 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/targeting-the-dna-repair-chromatin-modifier-protein-smyd3-as-a-novel-epigenetics-cb63efdfe9501123 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-imaging-characteristics-of-cervical-ossification-of-the-posterior-l-73868998a7563784 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-randomized-controlled-trial-of-a-computer-based-intervention-to-increase-inter-e37187b75de3a1bc 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/relationship-between-the-oral-microbiome-and-post-surgery-aspiration-pneumonia-i-05661ba74407e6e7 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-radiological-outcomes-between-stemless-and-stemmed-anatomic-total-s-a760dfc92dc37bf5 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/prophylactic-administration-of-caffeine-reduces-bronchopulmonary-dysplasia-in-ve-d03f54d0dfedd103 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/model-construction-and-validation-of-dual-energy-ct-multi-parameters-combined-wi-54c3ed37fa0f89ab 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/oliceridine-versus-sufentanil-based-postoperative-pcia-after-orthopedic-fracture-55887b1a9cc29bb9 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/uncovering-drug-related-problems-in-hospitalised-cancer-patients-and-their-assoc-efc4570e5b32231c 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/emerging-of-i-bla-i-sub-ndm-5-sub-in-i-providencia-rettgeri-i-and-i-morganella-m-befc2442fad249cc 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/12-year-experience-with-rapid-pcr-for-carbapenemase-producing-enterobacteriaceae-d7ace291c1e0dd6d 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sample-size-calculation-for-the-sequential-multiple-assignment-randomized-trial-b663246046ad92ac 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/translation-cultural-adaptation-and-validation-of-the-italian-food-allergy-quali-bf4cfc77b705b2e7 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-insufficient-publication-of-early-phase-clinical-trials-in-oncology-3892fd431663f8c1 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/safety-and-efficacy-of-i-lacticaseibacillus-rhamnosus-i-lra05-i-limosilactobacil-d6c57838e315bd89 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/serum-calcium-dynamics-and-risk-of-all-cause-hospitalization-and-mortality-in-he-1b56fc841056cc7c 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/antibiotic-timing-in-immunocompromised-patients-effective-therapy-as-one-piece-o-3e7e6c16bfba0086 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nucleotide-binding-oligomerization-domain-2-independent-colonization-by-i-turici-2670991088fd6e2d 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/formulation-and-systemic-therapy-a70251322316a57d 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effects-of-positive-and-negative-peer-modelling-versus-neutral-social-interactio-b8eb188f4c130a5a 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/i-cyp2c19-i-genotype-guided-p2y12-inhibitor-therapy-optimization-in-patients-at-eaf494461dbb7efa 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/innovative-therapies-under-clinical-development-for-als-treatment-part-2-biologi-8f189a5884c96a74 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-sensorimotor-training-on-pain-disability-kinesiophobia-and-quality-of-43617167d13bd661 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/plga-nanoparticles-co-loaded-with-resveratrol-and-doxycycline-for-dual-action-pe-939ca4ac398814e2 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-hematological-profiles-of-patients-with-burning-mouth-syndrome-acro-022457e51f90569e 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/body-composition-geography-and-ethnicity-understanding-the-associations-with-hea-83511d3ec99ead0c 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/osteoporosis-in-internal-medicine-outpatients-sex-specific-disparities-in-preval-be9fba067a2d76f0 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/multiple-drugs-79b281295c5b0029 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/laxatives-e366fbaab16cdd6e 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/lacosamide-trazodone-b8041cc37ac44beb 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/immune-globulin-34c51d4da30e4ce6 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/carbamazepine-4d56aaef213bd843 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/anabolic-steroids-19eb37cacfa42305 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/amfetamine-086d459f4e7fe4f2 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/antibody-drug-conjugate-related-pulmonary-aes-in-patients-with-lung-cancer-47aa3ae7f1966794 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/early-detection-and-intervention-in-at-risk-mental-states-rationale-structure-an-6929ea0ddf9d2682 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/improving-clinical-trial-design-in-low-back-pain-insights-from-studies-of-gabape-021af854b4928b1e 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/temporal-adaptive-transfer-learning-for-clinical-language-models-d7c2ca1be9632c5d 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-statistically-validated-ensemble-learning-framework-for-diabetes-prediction-us-2198a09ac2ef6a74 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/dentofacial-injuries-associated-with-e-scooter-use-a-narrative-review-of-the-int-25eb538c97f0ffca 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-outcomes-of-different-endoscopic-frontal-sinus-surgical-approaches-in-p-898283f0015f373f 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-course-and-treatment-outcomes-of-vulvar-condylomas-in-immunocompromised-6b3bbccb333263de 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/serum-nos1ap-concentration-association-with-clinical-polymorphism-of-schizophren-7ec98554276649f2 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-blended-learning-approach-to-online-dbt-skills-training-preliminary-clinical-o-47b9555f795b973d 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-genomics-reveals-genotype-phenotype-concordance-and-cryptic-resistom-623e614c1127a63a 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-rapid-molecular-detection-method-for-streptococcus-agalactiae-based-on-bacteri-46af29dbe8480bc6 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/histological-validation-of-barium-filled-vascular-channels-detected-by-high-reso-c3e6ce88dd5aaccb 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/behavioural-and-psychological-symptom-determinants-of-carer-burden-across-clinic-7864b1d2a21d3d14 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/in-vitro-approaches-for-modelling-gut-liver-crosstalk-in-drug-induced-liver-inju-62e7d0628aaa74b9 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/connective-tissue-graft-wall-technique-for-mandibular-class-ii-furcation-defects-abd37892f8f7e0d0 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-of-a-biorelevant-in-vitro-release-system-and-level-a-in-vitro-in-viv-9bf74a4eaa5cf8e2 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-the-fda-s-new-psychedelic-framework-actually-means-for-the-clinic-82547d1a0aed17aa 2026-09-11T23:49:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/scholar-rock-wins-fda-approval-for-first-drug-to-target-sma-muscle-loss-54ed2153766193cd 2026-09-11T23:33:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/drugging-the-undruggable-the-melbourne-biotech-taking-on-the-world-e50fad8ac922c69e 2026-09-11T22:24:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/china-resources-sanjiu-medical-pharmaceutical-co-ltd-approves-interim-dividend-f-7f694037475f400a 2026-09-11T20:52:53.000Z weekly 0.7 https://www.pharmaradar360.com/article/china-resources-boya-bio-pharmaceutical-group-co-ltd-announces-board-changes-fbae6992f109587a 2026-09-11T20:51:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-pharmaceutical-announces-major-senior-notes-financing-61e3a7f427a0147b 2026-09-11T20:43:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/could-tavapadon-change-parkinson-s-care-0b231a547acc5969 2026-09-11T20:40:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/axios-live-research-and-manufacturing-investments-boost-philadelphia-s-biotech-r-7d5c80b74d9a41bd 2026-09-11T20:37:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/exel-stock-slides-after-fda-adds-three-months-to-cancer-drug-review-william-blai-a4e0d321ec05963d 2026-09-11T20:19:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/phase-3-summit-trial-tests-axs-05-for-smoking-cessation-c2a2ddb8654b9893 2026-09-11T20:12:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/west-pharmaceutical-stock-gains-after-insider-sale-and-strong-q2-figures-84d8fd9320071891 2026-09-11T19:52:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/anmat-emitio-una-carta-de-advertencia-a-csl-behring-s-a-por-incumplimientos-a-la-6974219701c6349a 2026-09-11T19:32:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/assisted-dying-bill-defeated-in-house-of-commons-dd8a68cc3b3c1663 2026-09-11T19:07:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/staunch-biotech-competition-spurs-new-secretive-tactics-shifts-investor-approach-bef2c24268292855 2026-09-11T19:07:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/takeda-bets-on-brazil-to-expand-dengue-vaccine-sales-4712091b388d5fff 2026-09-11T19:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/thailand-seeks-pharma-deals-to-expand-medical-research-and-production-505d03828b78bd99 2026-09-11T18:52:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/gout-pipeline-2026-fda-updates-therapy-innovations-and-clinical-trial-landscape-687f3aa04173aaa0 2026-09-11T18:34:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-more-effectively-using-registries-to-support-patient-centered-reg-59f274e1114bf6a6 2026-09-11T18:34:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-accelerating-drug-repurposing-for-rare-neurological-neurometaboli-c16144d3c82284b1 2026-09-11T18:32:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-intranasal-rapid-acting-vaccine-for-all-seasonal-and-pandemic-inf-b7dc8c5747d85bdf 2026-09-11T18:32:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-advancing-a-vaccine-targeting-genetic-amyotrophic-lateral-scleros-f895ba56b82d2329 2026-09-11T18:27:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-a-personalized-prevention-roadmap-for-the-future-healthcare-1c2ab4d4a8f60b84 2026-09-11T18:27:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-boosting-the-reduction-of-the-environmental-impact-of-pharmaceuti-82c038d6089768d0 2026-09-11T18:27:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/opc-pharmaceutical-joint-stock-company-announces-change-in-certificate-of-busine-fe6de6c8360ed9ba 2026-09-11T18:21:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/neonc-technologies-holdings-briacell-therapeutics-and-oncolytics-biotech-have-re-fc8f2dcdb12dee3b 2026-09-11T18:21:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/healey-meets-with-biotech-startups-to-hear-about-financing-needs-d431d6eccb964475 2026-09-11T18:06:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/exelixis-stock-slips-as-fda-delays-cancer-drug-review-analyst-weighs-in-05e0e8ddba9506b8 2026-09-11T18:02:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/exelixis-stock-slips-as-fda-delays-cancer-drug-review-exelixis-nasdaq-exel-34a54ae1f51149f0 2026-09-11T18:02:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/ukrainian-pharma-exporters-urge-govt-to-establish-procedures-for-renewing-gmp-ce-1a18bf1597d22baf 2026-09-11T17:51:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/leen-kawas-how-to-build-more-resilient-medicine-supply-chains-8d03a93b3e0cc9a0 2026-09-11T17:48:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/cybin-cn-help-falls-5-91-as-clinical-stage-risk-and-phase-3-expectations-pressur-cdbe00e558c3223e 2026-09-11T17:38:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/top-biotech-picks-from-needham-company-for-second-half-of-2026-ee74fb0087d5cc48 2026-09-11T17:28:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/gregg-gorniak-on-turning-dscsa-compliance-into-strategic-opportunity-b1bece38c56b9d17 2026-09-11T17:27:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/sartorius-stedim-stock-gains-support-as-q2-margins-hold-and-analysts-stay-positi-f53652650cff630f 2026-09-11T17:12:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/freedom-broker-expects-a-correction-in-the-u-s-biotech-sector-2c9dd0505e15f6d0 2026-09-11T16:55:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/system-secures-us-20-million-as-peptide-wellness-market-accelerates-10b30ecfaa2a980c 2026-09-11T16:53:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/scancell-s-phase-3-melanoma-vaccine-trial-moves-toward-launch-raising-long-term-f055cd7f8d7dbdcf 2026-09-11T16:41:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-patients-with-the-same-cancer-respond-differently-to-treatment-a60157c4a2114df7 2026-09-11T16:27:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/weekly-buzz-jnj-wins-fda-nod-axgn-hcwb-strike-deals-roiv-azn-gpcr-lead-clinical-ee700ea0e8ab3089 2026-09-11T16:06:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/amgen-drops-10-on-a-trial-it-didn-t-even-run-2a676a36e7440c76 2026-09-11T16:05:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/psychedelics-are-on-the-fda-s-mind-098b13158b5d2c80 2026-09-11T16:04:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-extends-review-of-exelixis-colorectal-cancer-drug-candidate-2245083406727d54 2026-09-11T16:02:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/maharashtra-fda-suspends-199-eatery-licences-over-hygiene-7923dd3ae5553ace 2026-09-11T15:55:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/clarity-on-ai-responsibilities-in-healthcare-needed-national-commission-says-9f92ea5d94637140 2026-09-11T15:52:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmtech-weekly-roundup-september-11-2026-86af1c68f7295979 2026-09-11T15:47:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/new-fda-drug-approvals-august-2026-391a20e49e8f59a6 2026-09-11T15:45:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pancreatic-cancer-drug-may-also-help-fight-treatment-resistant-lung-cancer-aafc03201b52ab40 2026-09-11T15:44:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/gregg-gorniak-what-changed-in-five-years-of-dscsa-ca123a64e61f2012 2026-09-11T15:40:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/simultaneous-anaerobic-bioreactor-could-accelerate-sustainable-biomanufacturing-ae1dbbfbb1b962fd 2026-09-11T15:36:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-grants-final-approval-to-cabozantinib-capsules-across-multiple-solid-tumor-i-5fa070859ffd2443 2026-09-11T15:33:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/yarrow-brings-in-more-cash-abbvie-drug-succeeds-in-menstrual-migraine-trial-5b5adec38efa9e62 2026-09-11T15:28:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/duopharma-biotech-detects-unauthorised-system-access-attempt-01f83664a547773a 2026-09-11T15:27:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-grants-orphan-drug-status-to-lundbeck-s-asedebart-for-cushing-1eb4b1bc267f4c3f 2026-09-11T15:22:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/news-by-cnbc-tv18-on-tradingview-2026-09-11-cnbctv-df10e080b094b-0-4a5c05ed391864b9 2026-09-11T15:17:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/sex-ratios-at-birth-in-the-uk-2018-to-2022-7dbac71278ce6443 2026-09-11T15:09:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/deep-learning-system-detects-lesions-in-sacroiliac-joints-576cfe05e4d10fd9 2026-09-11T15:01:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/ptc-therapeutics-at-cantor-healthcare-conference-sephience-drives-growth-by-inve-b5e34fc199f16124 2026-09-11T14:48:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/working-for-dhsc-7fde6c0568507ce7 2026-09-11T14:39:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/decision-orphan-registered-medicinal-products-39e75e2ced1518f0 2026-09-11T14:20:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-expands-hyrnuo-use-in-her2-mutated-lung-cancer-c8473990dcc2cb27 2026-09-11T14:14:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/advanced-therapy-medicinal-products-regulation-and-licensing-in-uk-59aee4b062d03eb4 2026-09-11T14:11:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-pharma-s-next-ai-challenge-is-supervision-not-adoption-627d3deb812bd7dd 2026-09-11T14:09:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-fda-extends-review-of-exelixis-cancer-drug-8757b11d14127d07 2026-09-11T14:05:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/watch-conversations-on-america-s-global-biotech-leadership-0e8139d8aefabfa4 2026-09-11T14:04:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-drags-peers-down-with-triple-asset-stumble-4768c8eda32578b3 2026-09-11T13:52:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-delays-approval-decision-for-exelixis-tyrosine-kinase-inhibitor-in-colorecta-ab8e72d19005bfd7 2026-09-11T13:52:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-future-of-ras-inhibitors-b9331991fc80225f 2026-09-11T13:48:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-pharmaceutical-logistics-comes-together-d3a682022830edce 2026-09-11T13:47:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/5-things-to-know-in-life-sciences-week-of-sept-7-2026-421ed658cac3010f 2026-09-11T13:45:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-extends-exelixis-zanzalintinib-review-by-three-months-pushing-decision-to-ma-71428bb12c3e3400 2026-09-11T13:45:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/usfda-imposes-partial-clinical-hold-on-biohaven-s-epilepsy-drug-over-rodent-find-92a0f4f1b1601737 2026-09-11T13:43:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/pneumococcal-disease-cases-caused-by-serotypes-not-covered-by-pcv13-ce6e5496ced9fd89 2026-09-11T13:42:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/pneumococcal-disease-cases-caused-by-serotypes-covered-by-pcv13-2ddf38f53562a4bd 2026-09-11T13:42:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/cancer-drug-shortages-keep-disrupting-patient-care-6e2e3af5fd0b345d 2026-09-11T13:41:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/eli-lilly-completes-acquisition-of-ataibeckley-initiates-delisting-from-nasdaq-69f1dc69cfd406a7 2026-09-11T13:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/novo-holdings-and-leading-international-funds-are-investing-nearly-dkk-60m-in-a-7baec2cae950d5a3 2026-09-11T13:29:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/top-investor-urges-novartis-for-stronger-acquisition-oversight-after-m-a-and-tri-75168779bfdde9ca 2026-09-11T13:28:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-fda-extends-review-of-exelixis-cancer-drug-97cc7bfefd52c9ea 2026-09-11T13:19:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/ers-2026-bmi-type-2-inflammation-and-asthma-attack-risk-3aedc94d1f105ada 2026-09-11T13:08:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/new-light-emitting-nanoparticles-can-detect-subtle-chemical-differences-to-enhan-67d29ed1f086abd0 2026-09-11T13:01:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/lundbeck-drug-candidate-granted-another-us-fda-designation-9f040c75940d5b94 2026-09-11T13:00:53.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-s-atogepant-delivers-positive-phase-3-results-in-menstrual-migraine-b94ffc90724c6cb9 2026-09-11T13:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/astrazeneca-s-etcamah-falls-short-of-key-phase-iii-endpoint-in-breast-cancer-tri-5928c45ebac516f1 2026-09-11T13:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/14-l156-d-bio-organic-apple-peach-mango-6-months-lupilu-94ba913aacaf92bb 2026-09-11T12:52:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/decision-medical-devices-given-exceptional-use-authorisations-550b955b3ef9248a 2026-09-11T12:39:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/india-s-biotech-growth-needs-more-long-term-capital-says-expert-b0d7e83756aece93 2026-09-11T12:31:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/this-week-in-science-poop-concrete-hot-ice-and-more-42a5bda2583b76a4 2026-09-11T12:30:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/singapore-launches-biotech-focused-boston-hub-to-build-on-centuries-old-bond-b89995faef2f0ae8 2026-09-11T12:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/frazier-adds-1-1b-to-small-and-mid-sized-biotech-fund-ee5879e810cd4a42 2026-09-11T12:29:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/kenya-s-wealthy-merali-family-acquires-stake-in-pharmaceutical-glass-plant-0ddbfae56327c1a6 2026-09-11T12:26:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/eppendorf-launches-refrigerated-centrifuge-5811-r-aaa328684245d693 2026-09-11T12:19:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/report-an-outbreak-of-acute-respiratory-infection-in-an-adult-social-care-settin-4b8ec42924935cd1 2026-09-11T12:14:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/should-you-bet-big-on-drugmakers-vaneck-pharmaceutical-etf-vs-invesco-healthcare-6bf4962a35aab8ac 2026-09-11T12:13:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-download-biotech-s-future-and-cheaper-cleaner-steel-69a3d6cc2f2a0a2f 2026-09-11T12:10:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sterlitech-launches-benchtop-membrane-filtration-systems-4c0ec37e526d2019 2026-09-11T12:03:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-extends-review-of-exelixis-drug-application-for-metastatic-colorectal-cancer-623f07bc4551e9d8 2026-09-11T12:01:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/profitable-biotech-incyte-forms-handle-as-institutional-buyers-load-up-on-stock-e395f7467425a742 2026-09-11T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/transition-of-the-icelandic-medicines-agency-s-website-in-full-swing-c750fd2961bf03e7 2026-09-11T11:59:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/mrna-cancer-vaccines-biggest-barriers-to-market-a1a5e5c1027f15da 2026-09-11T11:56:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/u-s-fda-extends-review-of-exelixis-cancer-drug-deaffdf4f5a748a4 2026-09-11T11:49:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/anmat-evaluo-y-libero-mas-de-430-lotes-de-vacunas-entre-junio-de-2025-y-mayo-de-379e0cb77fd0e730 2026-09-11T11:49:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-extends-review-timeline-for-exelixis-cancer-drug-19d15b23009bb8c7 2026-09-11T11:33:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/frost-sullivan-presents-the-global-gene-therapy-crdmo-technology-innovation-lead-05419dc90ac4e4e3 2026-09-11T11:28:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biohaven-s-epilepsy-drug-hit-with-fda-clinical-hold-115921639fbaab9b 2026-09-11T11:02:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-investors-may-respond-to-sellas-life-sciences-group-sls-phase-3-trial-nears-36e1e2f8d7b894f7 2026-09-11T10:29:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-early-scale-cpc-biotech-and-multiply-labs-smoothen-cell-therapy-automation-b-cb9bcf29049b507a 2026-09-11T10:27:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/shanghai-henlius-biotech-says-nda-for-120-mg-biosimilar-denosumab-hlx14-accepted-c33c1fb7dab637a0 2026-09-11T10:26:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/mrkon-risks-explained-keytruda-dependence-patent-expiry-clinical-trials-and-toke-0f495729ddaa03b6 2026-09-11T10:21:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/poland-s-case-against-eu-wastewater-rules-boosted-by-advocate-general-opinion-0cb3bd178f9e4c11 2026-09-11T10:18:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/angelman-drug-partner-for-research-alliance-iii-racc-eyes-2029-data-6f76cf896ec6330e 2026-09-11T10:04:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/estates-safety-fund-initial-schemes-and-associated-funding-allocations-2026-to-2-578511fd55580096 2026-09-11T09:54:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/set-yourself-up-for-a-strong-2027-2-pharmaceutical-stocks-to-buy-in-september-7c5df69ea3cb3fa3 2026-09-11T09:53:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/astrazeneca-shares-phase-3-results-for-imfinzi-plus-imdelltra-in-extensive-stage-bb2e83d5304d0724 2026-09-11T09:50:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-tartan-army-to-biotech-deepening-scotland-s-ties-with-boston-through-new-li-882a8830a7c1ede8 2026-09-11T09:40:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/az-s-copd-drug-cuts-flare-ups-in-two-phase-3-trials-1e42b428339da8ba 2026-09-11T09:35:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/set-yourself-up-for-a-strong-2027-2-pharmaceutical-stocks-to-buy-in-september-8cc69ed199f1afbf 2026-09-11T09:35:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/head-of-german-venture-fund-sees-big-potential-in-danish-biotech-but-investors-a-cbacdcd980c6a8e4 2026-09-11T09:35:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/are-you-working-with-the-non-clinical-package-for-clinical-trial-applications-se-381cb66138accd14 2026-09-11T09:34:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/rewriting-the-rules-of-genetic-medicine-with-trna-therapeutics-beyond-biotech-aee67803a2f832f6 2026-09-11T09:33:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/trial-misses-prompt-shake-up-call-from-major-novartis-stockholder-9b04ea1f348cb183 2026-09-11T09:27:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-regulators-ask-when-ai-touches-a-drug-application-601c189441f030a0 2026-09-11T09:27:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/key-approvals-positive-study-results-and-a-partnership-deal-to-fast-track-new-me-4a3eb1cbd863abcd 2026-09-11T09:25:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/shanghai-henlius-biotech-inc-announces-acceptance-of-new-drug-application-for-12-deaaab0cc42dfe4b 2026-09-11T09:20:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-drug-meets-phase-3-goal-in-menstrual-migraine-f35f3b3a549baf53 2026-09-11T09:00:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/meet-the-under-35s-shaping-the-future-of-biotech-0e01cfbafd7d371b 2026-09-11T09:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/aprecia-pharmaceuticals-am-is-an-important-expansion-of-the-pharmaceutical-manuf-fa4992349a80da17 2026-09-11T08:51:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/anavex-life-sciences-to-discuss-pediatric-inclusion-in-rett-syndrome-trial-by-in-b5f75a08654d2790 2026-09-11T08:49:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-for-climate-resilience-fund-31985e360beccdf6 2026-09-11T08:43:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/moderna-begins-phase-1-clinical-trial-of-ebola-vaccine-against-strain-behind-drc-0f15edae8af6e558 2026-09-11T08:26:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-advisers-narrowly-vote-to-add-6-peptides-to-a-drug-compounding-list-what-s-n-05eb0af1ede61b6f 2026-09-11T08:26:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/reporter-s-notebook-k-biopharma-licensing-deals-are-getting-better-not-just-bigg-744ac6deb31a7e39 2026-09-11T08:24:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-13-september-2026-1016782b910b7d0c 2026-09-11T08:22:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/astadaily-earns-purity-award-from-clean-label-project-d798f43275060d64 2026-09-11T08:20:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/jpmorgan-initiates-dianthus-stock-at-overweight-135-target-76d704bda903e96f 2026-09-11T08:12:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/reporter-s-notebook-k-biopharma-licensing-deals-are-getting-better-not-just-bigg-c15b62c6b02b8567 2026-09-11T08:02:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-students-must-step-out-of-comfort-zones-embrace-multiple-roles-suchitra-bd66bfb839665905 2026-09-11T07:57:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-clears-prelude-s-prt13722-phase-1-trial-in-hr-positive-breast-cancer-33a29eff5efb8a93 2026-09-11T07:33:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/limitless-biotech-coupon-code-pct15-save-15-on-research-peptides-b07e64035e883a26 2026-09-11T07:22:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/kenanga-launches-world-first-hang-seng-biotech-index-structured-warrants-258d523c61bb1937 2026-09-11T07:16:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/marquis-who-s-who-honors-kenneth-hesterman-for-expertise-in-pharmaceutical-accou-4cd9960720360d81 2026-09-11T07:02:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-excipients-market-to-reach-usd-24-88-billion-by-2035-at-8-1-cagr-e55ec71af1e14859 2026-09-11T06:57:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/velocity-clinical-stitch-expand-partnership-across-70-sites-to-boost-screening-a-e913a53837fd85f4 2026-09-11T06:48:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-says-closely-watched-cholesterol-study-failed-to-meet-goal-c974947767e107ee 2026-09-11T06:45:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/phase-3-study-shows-aqivc-superior-to-comparators-in-older-adults-b7ea1dfa91dfde4e 2026-09-11T06:38:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/reg-rtw-biotech-opp-additional-investment-in-encoded-therapeutics-06ce266c777880ac 2026-09-11T06:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/orzeyful-approval-might-change-the-case-for-investing-in-takeda-stock-8b50302be3cb1bfe 2026-09-11T05:58:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-strong-biotech-ip-strategies-get-right-and-where-weak-ones-break-down-a2b121fe65165341 2026-09-11T05:43:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/comment-climate-change-threatens-pharmaceutical-companies-6987587302b518a2 2026-09-11T05:13:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/henlius-86cc303c86469a6e 2026-09-11T05:10:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/former-head-of-takeda-pharmaceutical-dies-at-80-6fc269c48465eb75 2026-09-11T05:03:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/active-biotech-ab-publ-sto-acti-is-breakeven-near-585e562e6ced9952 2026-09-11T04:30:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-partially-halts-trials-of-sk-biopharmaceuticals-epilepsy-drug-candidate-e77116af26fe1e1f 2026-09-11T04:17:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/west-pharmaceutical-services-senior-vp-favorite-sells-2-77m-in-stock-9fe9896a7541d2cb 2026-09-11T04:16:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/jiangsu-handian-biotech-lands-tens-of-millions-of-yuan-in-strategic-round-89239b47de33a798 2026-09-11T04:01:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/ex-takeda-pharmaceutical-head-hasegawa-dies-at-80-07ac3ad58f8939ed 2026-09-11T03:54:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/paradigm-biopharmaceuticals-secures-additional-funding-for-phase-3-clinical-tria-54c8d0d78e14ca49 2026-09-11T03:19:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/paradigm-biopharmaceuticals-asx-par-draws-final-us-2-million-tranche-as-phase-3-a44324072bfb26c8 2026-09-11T03:18:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-halts-sk-biopharm-s-opcalim-novartis-12-billion-drug-fails-phase-3-0ab09b28ac07fe98 2026-09-11T03:10:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/paradigm-biopharmaceuticals-secures-additional-funding-for-phase-3-clinical-tria-ddb4fb8de8310392 2026-09-11T03:07:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/laser-therapy-offers-new-hope-for-inoperable-pancreatic-tumors-aa7039f94cc04951 2026-09-11T03:01:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/viking-therapeutics-aims-high-at-92-target-but-clinical-risks-remain-cdae87387dc82248 2026-09-11T02:54:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/data-aggregation-drives-ai-s-impact-on-clinical-supply-chains-c09c4abbac6eea8f 2026-09-11T02:41:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/more-than-28-000-bottles-of-blood-pressure-drug-recalled-fda-11bf9d424e5e5c88 2026-09-11T02:31:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/india-s-food-safety-crackdown-what-the-viral-raids-don-t-show-869bc1b6b56998d4 2026-09-11T02:08:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agenda-for-november-2026-cancer-treatments-ctac-meeting-3a6d1f5f98e260f8 2026-09-11T02:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/frazier-life-sciences-adds-1-1b-to-biotech-public-fund-lifting-it-to-2-8b-e142f1ed47f39964 2026-09-11T01:48:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/genscript-biotech-to-place-77-1-million-shares-at-hk-30-50-per-share-586a45444917dbb9 2026-09-11T01:29:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/annual-iipa-debate-2026-ku-fda-plan-major-food-safety-awareness-push-in-j-k-415bf82849db4727 2026-09-11T01:24:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/is-teva-pharmaceutical-industries-nyse-teva-still-a-bargain-or-fully-priced-22afb570e071b7c5 2026-09-11T01:16:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/is-teva-pharmaceutical-industries-nyse-teva-still-a-bargain-or-fully-priced-a490fd25a3336a5e 2026-09-11T01:15:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/exclusive-genencell-treatment-with-elevated-liver-enzymes-approved-for-clinical-775a5811d53df627 2026-09-11T01:11:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-fda-pauses-new-enrollment-in-biohaven-s-epilepsy-drug-trials-f4e06e3e7cd27817 2026-09-11T01:05:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-places-hold-on-opacalim-trials-sk-biopharmaceuticals-says-limited-relevance-73bbabf1168b65b2 2026-09-11T00:38:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/tukaram-mundhe-s-food-order-for-festivals-what-maharashtra-fda-commissioner-said-3dd813ddcd70dbc5 2026-09-11T00:10:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/megazonecloud-begins-building-hanmi-pharmaceutical-s-quality-assurance-ai-agent-34906fa2a5c01536 2026-09-11T00:06:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/novo-nordisk-advances-new-injectable-obesity-drug-in-key-phase-3-trial-55906840ab9c4121 2026-09-11T00:01:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/gsk-filed-form-6-k-130362fb32f7b414 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-heart-lung-and-blood-institute-notice-of-meeting-a3006d086a794e13 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medical-devices-cardiovascular-devices-classification-of-the-cardiovascular-mach-212eaf111483ed36 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-omb-review-comment-reque-577ad723f444fe54 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/emran-mohammad-rn-aprn-cnp-decision-and-order-c222547fc36d6725 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/joseph-john-stubbers-iii-d-o-decision-and-order-56e3d57bd217be2e 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cheryl-white-n-p-decision-and-order-6910fc9ec09361e7 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/craig-cohen-dpm-decision-and-order-bac086480e607f05 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/notice-of-supplemental-funding-appalachian-region-healthcare-support-program-eb7a15e20f6e765d 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/notice-of-supplemental-funding-infant-toddler-court-program-state-awards-556a097130f48a79 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-public-comment-requ-cbd46bd70ec39a02 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/amending-over-the-counter-monograph-m020-sunscreen-drug-products-for-over-the-co-bf1f21ba8881a138 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-med-93720515e76d644f 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-office-of-management-and-c7cf00b962ad7623 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/notice-of-supplemental-funding-rural-hospital-stabilization-pilot-program-f42ef2358c137743 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-institute-on-aging-amended-notice-of-meeting-05a388dc6e88ab98 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-institute-of-diabetes-and-digestive-and-kidney-diseases-amended-notice-943f33d3924a19c8 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-e4c7ec9101c7b4ed 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/study-shows-benefits-of-coffee-for-liver-health-db0567cadb2381ba 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-race-for-the-next-big-weight-loss-drug-is-on-and-china-wants-in-4ca0025474e6d592 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effectiveness-and-safety-of-a-new-standardised-treatment-protocol-based-on-initi-e56b8bfccea093ab 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sex-specific-efficacy-of-acetazolamide-for-acute-mountain-sickness-a-randomised-ee87c8ca10895aa3 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-services-do-people-seek-when-they-visit-a-community-pharmacy-care-clinic-d0b530ddc5e44386 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/managing-patients-with-heart-failure-a-contemporary-practice-tool-for-pharmacist-7c408d6b46d4237c 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medication-safety-in-indigenous-communities-challenges-and-interventions-1bf49ca019f7d0e2 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ten-year-analysis-of-publications-by-quebec-hospital-pharmacists-8f6c95173b5e694f 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-related-problems-in-older-adults-with-mild-cognitive-impairment-or-dementia-96f624acc8f4f4a9 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/management-of-a-patient-with-a-ticagrelor-rosuvastatin-interaction-an-algorithm-9d231ffd5b5bc159 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-call-for-the-generalist-pharmacist-bdb545612f6c918f 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/heiguteng-zhuifeng-huoluo-capsule-alleviates-osteoarthritis-associated-with-glyc-e816d5aada6daaeb 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/dose-optimization-of-deuruxolitinib-in-adults-with-alopecia-areata-a-phase-2-ran-732d8bf97a9e319a 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/efficacy-of-tdcs-primed-itbs-in-major-depressive-disorder-a-randomized-sham-cont-b40827847a532095 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/trastuzumab-botidotin-versus-trastuzumab-emtansine-in-human-epidermal-growth-fac-d39b584c172d264d 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/plasma-versus-whole-blood-tacrolimus-concentration-and-outcomes-after-kidney-tra-43fea2d7c00d92c0 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/late-onset-multiple-acyl-coa-dehydrogenase-deficiency-madd-glutaric-acidemia-typ-26ad462a8ff18b6e 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/benchmarking-drug-library-compliance-and-alert-rates-in-smart-infusion-pumps-a-m-cc042761c50bfb5e 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/successful-management-of-generalized-drug-influenced-gingival-enlargement-a-clin-a0dff0eeba02fdca 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-phenotypes-and-factors-associated-with-systemic-involvement-in-pediatri-bb23bbedc93d5e22 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-ictal-interictal-continuum-a-comprehensive-review-for-the-clinical-epileptol-1d28a0773cd7a283 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-impact-of-medical-procedure-in-needle-stick-injuries-among-healthcare-practi-a625c88de71da316 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/knowledge-attitudes-and-practices-regarding-hypertension-prevention-among-medica-95ce3ccfb7d13a35 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/acupuncture-care-for-a-patient-with-tennis-elbow-lateral-elbow-tendinopathy-a-ca-55448e3e6a6b64ce 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/i-ll-see-it-when-i-believe-it-73965d6ba86bbf24 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-practitioner-s-guide-to-ericksonian-choice-architecture-7ba5e46554ae733e 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effectiveness-of-olfactory-training-and-topical-corticosteroids-for-persistent-p-284ef17782a9bce4 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/future-directions-b7312a04957ae1cb 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/teaching-the-invisible-a-game-based-simulation-for-learning-health-care-economic-7ea5cdfe5504fe20 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pre-diagnostic-identification-of-cholestatic-liver-diseases-using-integrated-cli-89d880bf052825c6 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/chemical-fingerprinting-and-simultaneous-determination-of-main-compounds-combine-c618963982a18705 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/localization-of-advanced-drug-delivery-manufacturing-in-saudi-arabia-through-tec-a5d3d641a0ae9b7d 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fused-spinopelvic-angle-in-adult-spinal-deformity-with-pure-sagittal-malalignmen-a50ebbefa1722eb4 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/predictive-analysis-of-social-determinants-of-health-in-posterior-cervical-spine-990d69caca0e348f 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/association-between-physical-therapy-and-mortality-in-older-patients-with-heart-9c687d7a8b736236 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hydrus-microstent-combined-with-cataract-surgery-in-pseudoexfoliation-glaucoma-v-da281f09101151ea 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/functional-status-and-postoperative-outcomes-after-left-pancreatectomy-for-pancr-ece63d7def3a3618 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/diagnostic-approach-and-therapeutic-management-of-spontaneous-esophageal-perfora-729725021ca6e7c5 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-implementation-and-clinical-validation-of-a-whole-genome-sequencing-non-inva-5efd029892d9731c 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/risk-stratification-of-acute-symptomatic-anterior-circulation-intracranial-ather-060335b18fc361ee 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-clinical-study-of-simotang-oral-liquid-combined-with-shenque-acupoint-applicat-d4b5d7677424f285 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fusion-level-selection-in-posterior-hemivertebra-resection-for-congenital-scolio-4356d58d5169b806 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/rethinking-ai-in-clinical-decision-support-a-framework-for-reciprocal-human-ai-i-1420c6c6866df483 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-efficacy-of-radix-arnebiae-oil-in-patients-undergoing-incision-and-drai-58f0e461772494f1 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fetal-behavior-as-a-window-to-later-gross-motor-function-a-10-year-follow-up-of-c8f670e65987c96e 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-laboratory-criteria-for-a-differentiated-approach-to-the-management-d489377a752957d5 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/efficacy-of-dapagliflozin-in-the-treatment-of-patients-with-signs-of-cardio-rena-d4a6bb4196d21d84 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-rationale-for-individualizing-secondary-prevention-in-patients-with-ath-c7a775dd082043ba 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/edukasi-tentang-hoaks-obat-dan-kesehatan-di-media-sosial-dengan-bijak-berselanca-5fa5e8f4010bbf01 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-characteristics-and-surgical-outcomes-of-split-cord-malformations-a-ret-a259bf8535951c1f 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluating-prevent-for-cardiokidney-outcomes-in-ckd-076f0a826668143c 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/executive-functions-and-conceptual-models-a-first-look-at-a-complex-topic-commen-237f2f36d13ca767 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/integrating-computed-tomography-and-magnetic-resonance-imaging-education-into-a-916bc317b1b11c9c 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/preparation-and-characterization-of-chitosan-co-acrylamide-hydrogels-for-control-6272337bb2bce876 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/enhancing-guideline-directed-medical-therapy-at-discharge-through-collaborative-61c425f8c65f8565 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-relevance-of-accuracy-in-in-house-3d-printing-in-craniomaxillofacial-su-5d29ff74d526eef8 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-theory-based-health-education-intervention-in-improving-exclusive-brea-3c22484e4d298979 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluation-of-the-feasibility-usability-and-preliminary-effects-of-an-mhealth-in-61c938230b152285 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-outcomes-of-cavaterm-thermal-balloon-endometrial-ablation-in-women-with-9a5696678c3b99a8 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/alveolar-ridge-preservation-using-advanced-platelet-rich-fibrin-versus-concentra-642458687bb7b17c 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluating-the-therapeutic-efficacy-of-a-modified-ketogenic-diet-in-children-wit-7bdc14cebb6eaee3 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-low-dose-esketamine-on-quality-of-recovery-after-gynecologic-laparosco-9565882e22d28941 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/salivary-lysozymes-anti-inflammatory-cardiac-medications-and-cardiovascular-mort-595fc7d8250f6e70 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-association-between-hormonal-contraceptives-and-lower-extremity-injuries-in-7f2bf0b2935043e0 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/uncertainty-and-novel-clinical-trial-designs-in-oncology-when-should-equipoise-m-9d09e54cf8511c76 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-discrimination-to-decision-external-validation-and-clinical-utility-of-a-di-fc08c4cab53491f2 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/oculomics-and-cardiovascular-disease-from-enthusiasm-to-clinical-reality-845c121fddcc7236 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/mitral-regurgitation-and-severe-aortic-stenosis-clinical-characteristics-prognos-56a6b86519668248 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/safety-and-efficacy-of-intratumoral-medi1191-an-il12-mrna-lipid-nanoparticle-plu-9feec652d62b5a63 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/spatiotemporal-mapping-of-tertiary-lymphoid-structure-heterogeneity-shapes-immun-b878c7a6750a845e 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/differentiation-between-bipolar-versus-unipolar-depression-by-ai-based-multimoda-10811a17d96af235 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/lignan-rich-norway-spruce-i-picea-abies-i-resin-extract-exhibits-anti-inflammato-bbbefd8591a7808a 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/alcohol-and-other-drug-policies-for-health-care-workplaces-evaluation-of-the-con-e99cec33373f8f7b 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/integrating-public-health-advertising-and-the-health-belief-model-to-predict-dia-a0939aee5e67c757 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/interesting-hurdles-in-the-solution-of-pharmaceutical-crystal-structures-using-p-3e514e35adab43a8 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/anterior-palpability-and-proptosis-as-clinical-predictors-of-ptosis-in-lacrimal-450fcdb8e69e20a6 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-factors-are-associated-with-shoulder-joint-pain-in-male-swimmers-including-2d4ac870140b4056 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/value-based-healthcare-scaling-value-based-care-through-surgeon-leadership-452cfb461f6acbc0 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pro-ctcae-in-oncology-drug-evaluation-cross-agency-review-of-regulatory-and-heal-e2676d3716a504eb 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/strengthening-the-pre-hospital-chain-of-survival-for-out-of-hospital-cardiac-arr-95603fb884f8a5ca 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/optimized-dosing-of-momelotinib-in-myelofibrosis-through-quantitative-medicine-a-82759c408af8a2d1 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/implementing-structured-and-collaborative-clinical-planning-for-comprehensive-hi-2ee6f77428200007 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-daffodils-to-drug-leads-amaryllidaceae-alkaloids-target-protein-translation-d152f81dc448462f 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/maladaptive-movement-in-eating-disorders-clinical-correlates-and-cross-cultural-88f05d3f85a94292 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gut-microecology-and-cardiovascular-disease-core-pathogenic-mechanisms-and-clini-3c2babc6119fff71 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/burnout-factors-for-pediatric-psychologists-across-career-stages-70a346964a211cd9 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/oligoclonal-band-count-as-a-marker-of-mri-lesion-burden-and-clinical-profile-in-750eee9cb00a292e 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-mri-features-associated-with-remission-following-biological-therapy-0d857f7086779929 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/repeated-perioperative-hypersensitivity-reactions-and-positive-challenge-testing-a6d40ff19fd054a0 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/safety-of-nonsteroidal-anti-inflammatory-drug-use-in-traumatic-brain-injury-579799c9f9af014a 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmacokinetics-of-loading-dose-vigabatrin-administered-via-enteral-tube-in-par-90af192c98b082d8 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/responsible-implementation-of-ehr-based-clinical-prediction-models-beyond-perfor-eecda7cc2a55f5b8 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07816575-comparative-efficacy-of-alpha-hydroxy-acids-with-and-without-nanocar-d7ef75d6761b1a5d 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07816510-combination-of-oral-antifungal-treatment-for-refractory-dermatophyto-702068d4be42e1c4 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07816328-investigation-of-a-remibrutinib-and-omalizumab-based-treatment-algor-03dcb9b7e3a5e14f 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07815626-phase-3-study-to-evaluate-the-efficacy-and-safety-of-human-growth-ho-6269ee1ed4d7a47c 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07815301-gradual-tapering-or-discontinuation-of-beta-blockers-after-stabiliza-7fc2e5dc6cbb93d7 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07814365-pbi-for-low-risk-breast-cancer-a312bf3a7dc39711 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07813949-evaluation-of-clinical-performance-shade-matching-and-patient-satisf-7c074338dfdf4687 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07714538-breath-research-narrow-validation-for-gastrointestinal-cancer-detect-8b45a742a232789e 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07597746-effects-of-a-combined-repetitive-transcranial-magnetic-stimulation-a-8effc8546335d7ad 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07597161-trial-of-device-that-is-not-approved-or-cleared-by-the-u-s-fda-38094db28f64d38d 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07593079-prostate-specific-membrane-antigen-psma-imaging-for-detection-of-res-b3e776fd82076549 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07575685-enhancing-cancer-care-restoreme-app-for-personalized-nutrition-and-a-35ec302ac93c9811 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07566156-enfortumab-vedotin-in-combination-with-pembrolizumab-vs-concurrent-c-5e6eb7a3af17cfa1 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07557420-efficacy-safety-pharmacokinetics-pharmacodynamics-and-immunogenicity-d9d2b2f8a4ba8e14 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07489378-nci-childhood-cancer-data-initiative-ccdi-led-pediatric-adolescent-a-c53e59732f23426f 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07416786-validation-of-nad-measurements-for-human-clinical-studies-38d39bd6fb10bbc7 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07391774-testing-whether-hormone-therapy-with-ribociclib-is-as-effective-as-c-950c4ddcb9c97097 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07388537-evaluation-of-the-clinical-spectrum-of-diabetes-and-obesity-in-youth-3033397525ec41f9 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07370974-effect-of-clinical-hypnosis-in-preoperative-anxiety-among-patients-u-4cedb6dad168e6e8 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07278739-testing-an-educational-program-to-improve-goals-of-care-conversation-4133918c2dd23ca2 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07226349-a-study-of-bg-75098-alone-and-in-combination-with-other-agents-in-ad-60a0ce7404bbdbf3 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07103109-impact-of-proximal-motor-control-exercise-on-scapular-muscles-activa-602738f19bfdff82 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07091149-digital-cognitive-behavioral-treatment-of-insomnia-in-youth-an-rct-e-3868d1851c216b7b 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06921850-a-study-to-assess-the-pharmacokinetics-and-safety-of-bimekizumab-in-05eaad6aa11825f1 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06920511-cognitive-rehabilitation-with-virtual-reality-in-parkinson-disease-93602a996fb80ba0 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06899633-multicenter-observational-descriptive-study-of-the-diagnosis-course-0e77eb58f35b55e8 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06681662-ephedrine-for-reducing-onset-time-of-rocurinium-in-elderly-patients-b768979f5853708d 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06562803-efficacy-and-safety-of-cytokine-adsorption-and-plasma-exchange-in-pa-06361ddfe1bd13c4 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06429761-phase-4-study-to-assess-the-safety-of-trastuzumab-deruxtecan-in-indi-8c232c7e7eca860c 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06292845-ex-vivo-tumor-visualization-and-resection-margin-assessment-using-to-458aae9925424cc4 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06200246-cardio-vascular-energy-transfer-and-ventriculo-arterial-coupling-in-ef954c69ea799072 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06200155-psilocybin-assisted-psychotherapy-in-patients-with-advanced-cancer-o-0d46d0afc351195a 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05985954-open-label-phase-1b-study-of-ulixertinib-and-cetuximab-or-ulixertini-f33b527d6a3e103a 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05924464-group-preconception-care-for-fertility-patients-592f3e630e81ffb8 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05920356-a-study-evaluating-sotorasib-platinum-doublet-combination-versus-pem-b413c482bc01e9dc 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05885555-a-study-of-ianalumab-vay736-in-patients-with-primary-immune-thromboc-0ecf7df0b9c75450 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05630794-testing-for-safety-and-colorectal-cancer-preventive-effects-of-onc20-79ca405eef852ea9 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05206357-study-of-the-adverse-events-and-change-in-disease-state-of-pediatric-2875f81dc33b08ab 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05201248-a-study-to-evaluate-adverse-events-and-change-in-disease-activity-of-7f89db7d619c8711 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05081609-a-study-to-investigate-safety-and-tolerability-of-transcon-il-2-alon-57848da0e56e142c 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05019885-the-efficacy-of-a-subanesthetic-doses-of-iv-ketamine-in-the-treatmen-87333c25d030c5eb 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04787848-chronic-widespread-pain-in-hiv-novel-mechanisms-and-therapeutics-d7b23319aa2468ca 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04166409-a-study-of-the-drugs-selumetinib-vs-carboplatin-and-vincristine-in-p-f4da250f1508000e 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04032470-boston-scientific-registry-of-deep-brain-stimulation-for-treatment-o-3c738a9bbf06c5fe 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03100149-a-study-to-evaluate-the-efficacy-of-prasinezumab-ro7046015-prx002-in-1ec734dd69af80b5 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct02880618-barostim-therapytm-in-heart-failure-with-reduced-ejection-fraction-a442fc9d8a1ae147 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct02824471-sickle-cell-disease-biofluid-chip-technology-scd-biochip-a841f72986de811d 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct01679132-barostim-neo-hypertension-pivotal-trial-fddc5137d692f938 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct00047996-blood-collection-for-research-related-to-certain-diseases-involving-ec5b5f5ff1528310 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/copd-clinical-trial-pipeline-gains-momentum-65-companies-lead-the-charge-in-pion-51928ee57120909b 2026-09-10T23:46:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/obesity-clinical-trial-pipeline-gains-momentum-80-companies-lead-the-charge-in-p-00145e11b672a229 2026-09-10T23:46:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-s-2026-ipos-deliver-broad-gains-through-august-5be01e38f285a85a 2026-09-10T23:40:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ctt-pharmaceutical-holdings-ceo-ryan-khouri-buys-175-in-stock-ba8ba3e61a362f04 2026-09-10T23:31:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-trials-new-mrna-cancer-vaccine-plus-keytruda-sharply-improves-melanoma-77a6de9d73d0071d 2026-09-10T22:14:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/canaccord-genuity-maintains-buy-on-helus-pharma-cuts-target-to-42-d3a308a8f221ddf5 2026-09-10T22:08:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-withdraws-publication-of-covid-shingles-vaccine-research-findings-0c9137b444e2e92a 2026-09-10T22:07:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/presidential-leadership-series-features-trustee-and-former-takeda-ceo-christophe-38714faec7ed3737 2026-09-10T21:57:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/cpc-biotech-multiply-labs-develop-robot-ready-cell-therapy-connector-21a5a057220ff310 2026-09-10T21:54:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/west-pharmaceutical-services-sr-vp-chief-hr-officer-sold-shares-worth-over-2-7m-e4a012d0bc83cc78 2026-09-10T21:40:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/west-pharmaceutical-nyse-wst-hr-chief-sells-stock-outside-a-10b5-1-plan-f09f4eb3b8e82826 2026-09-10T21:37:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/european-regulators-prepare-the-pharma-industry-for-future-changes-as-legislatio-fea13585a4f31be1 2026-09-10T21:32:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/new-phase-2-clinical-trial-initiating-in-2027-evaluating-psilocybin-assisted-the-b453b9741c0dd011 2026-09-10T21:10:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/david-samra-calls-for-novartis-board-shake-up-pharmexec-d325baf3d1a4dd3e 2026-09-10T21:06:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/west-pharmaceutical-services-inc-stock-outperforms-competitors-on-strong-trading-8d201788bc6ff87c 2026-09-10T21:04:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/krystal-biotech-at-cantor-healthcare-conference-pipeline-gains-pace-da48474dd512d462 2026-09-10T20:42:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/excipient-selection-strategies-to-mitigate-nitrosamine-risks-812ded3585d60c32 2026-09-10T20:26:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/west-pharmaceutical-nyse-wst-awards-ceo-37k-options-and-14-8k-rsus-vesting-throu-02890534117bc52a 2026-09-10T19:40:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/precision-trading-with-fortress-biotech-inc-9-375-series-a-cumulative-redeemable-7b2183f89cc3ac84 2026-09-10T19:10:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/quantum-biopharma-advances-multiple-sclerosis-drug-lucid-ms-toward-phase-2-trial-f972f351fbcb86aa 2026-09-10T19:02:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/committee-will-weigh-biotech-innovation-against-security-risks-6d75b2b5f7c94bf9 2026-09-10T18:42:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/biohaven-shares-plunge-as-fda-halts-new-enrollment-in-epilepsy-drug-trials-ba8d221d153c02a0 2026-09-10T18:41:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/encoded-secures-275m-for-dravet-syndrome-gene-therapy-ac2b33bda3009e77 2026-09-10T18:37:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-seeks-public-input-on-advancing-botanical-drug-development-ed74359bca572fc5 2026-09-10T18:25:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-declares-quarterly-dividend-260df77eb2bfb636 2026-09-10T18:25:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/5-best-psychedelic-stocks-for-2026-and-how-to-invest-723c0a3c104e3b21 2026-09-10T18:18:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/chemical-structure-formula-and-name-support-written-description-of-pharmaceutica-1d77f969ae2d3e5c 2026-09-10T18:11:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/quantum-biopharma-s-lucid-ms-advances-toward-phase-2-multiple-sclerosis-trial-af-2e6eaca0773422e8 2026-09-10T17:53:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-fda-pauses-new-enrollment-in-biohaven-s-epilepsy-drug-trials-088c0078107ecbf8 2026-09-10T17:37:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-extends-migraine-leadership-with-positive-phase-3-atogepant-results-in-me-5770650b6a275938 2026-09-10T17:04:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/hplc-degasser-upgraded-biotech-fluidics-launches-the-degasi-ng-platform-28b7579689b125bf 2026-09-10T17:03:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-products-with-device-only-patents-a-cross-sectional-analysis-5b12204246d6eec3 2026-09-10T16:47:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/anmat-actualiza-los-criterios-regulatorios-para-software-como-dispositivo-medico-ce78e29882f4f325 2026-09-10T16:46:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-drug-shows-significant-reductions-in-menstrual-migraine-days-0a66926b0c3b14b1 2026-09-10T16:41:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-news-from-around-the-world-96b51f3fd7c4a507 2026-09-10T16:40:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/seattle-biotech-brainchild-bio-raises-116m-to-advance-car-t-therapy-for-childhoo-6c114812ad208cfb 2026-09-10T16:34:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/centanafadine-receives-fda-approval-for-the-treatment-of-adhd-dd04c8e056bb32a3 2026-09-10T16:34:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/nhs-injury-costs-recovery-scheme-april-2025-to-march-2026-02e29b54f45a8fc7 2026-09-10T16:26:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/best-biotech-stocks-to-add-to-your-watchlist-september-10th-d8ab2eff220ca406 2026-09-10T16:04:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/xocova-offers-new-post-exposure-covid-19-prevention-option-for-adolescents-180741a4ba145920 2026-09-10T15:57:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/hsil-extends-biotech-index-to-malaysia-s-warrant-market-7d7be353577cf20e 2026-09-10T15:26:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/kala-shankle-on-what-comes-next-for-national-licensure-74efa622bca91473 2026-09-10T15:23:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/minister-agrees-to-review-pharmacy-amendments-to-health-bill-46a2c884d11eb4a4 2026-09-10T15:19:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/ai-changes-the-how-not-the-what-ccddb8218dba7492 2026-09-10T15:15:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/roivant-at-citi-summit-cash-rich-biotech-leans-on-three-pillars-60ac4a42be1a796f 2026-09-10T14:55:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/phase-3-trial-of-experimental-dm1-treatment-fails-to-hit-main-goal-47fea7492ee4aa03 2026-09-10T14:54:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-fda-pauses-new-enrollment-in-biohaven-s-epilepsy-drug-trials-2130c9870ed50f98 2026-09-10T14:45:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/burning-rock-biotech-limited-reports-earnings-results-for-the-second-quarter-end-fe9932e3452b9015 2026-09-10T14:37:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-fda-pauses-new-enrollment-in-biohaven-s-epilepsy-drug-trials-dfd4d9a9539fb316 2026-09-10T14:36:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/fifth-circuit-judges-press-louisiana-on-standing-as-mifepristone-stays-available-7803e41623ffd424 2026-09-10T14:30:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/high-consequence-infectious-disease-country-specific-risk-11ed7e663ad962ce 2026-09-10T14:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/ebola-and-marburg-haemorrhagic-fevers-outbreaks-and-case-locations-16b29cdb0bb31831 2026-09-10T14:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/syndromic-surveillance-weekly-summaries-for-2026-45747e3878253def 2026-09-10T14:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/remote-health-advice-weekly-bulletins-for-2026-0b8fbceac342c05c 2026-09-10T14:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/outbreaks-under-monitoring-in-2026-eb6ae222898106b1 2026-09-10T14:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-ambulance-syndromic-surveillance-weekly-bulletins-2026-6dee157afd1fba75 2026-09-10T14:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/gp-out-of-hours-syndromic-surveillance-weekly-bulletins-for-2026-f212a5a75078c06e 2026-09-10T14:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/gp-in-hours-weekly-bulletins-for-2026-dfebf391f225843d 2026-09-10T14:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/emergency-department-weekly-bulletins-for-2026-08abcdde2881ef86 2026-09-10T14:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-past-endpoints-11-winners-fared-as-the-biotech-industry-rebounded-b43f9ce8182c04f8 2026-09-10T14:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-security-market-competitive-landscape-analyzed-across-leading-glo-ae872b3a3ec772bd 2026-09-10T14:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/greater-philadelphia-regional-life-sciences-roundup-september-10-2026-a692fddd69a19c9d 2026-09-10T14:28:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/glenmark-and-south-piedmont-open-2-7-million-pharmaceutical-training-facility-0b4260fbc2643d82 2026-09-10T14:18:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-cracks-down-on-unsafe-food-banned-products-17cbcad470576ff1 2026-09-10T14:14:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/stalled-generous-globe-and-guard-initiatives-create-international-pricing-uncert-01e4dff956d74dff 2026-09-10T14:13:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-health-equity-champions-can-learn-from-pharmaceutical-sales-9d780c13222a1501 2026-09-10T13:59:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-places-partial-hold-on-biohaven-s-ion-channel-drug-f305595bf9c3c703 2026-09-10T13:58:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/environmental-monitoring-following-the-grenfell-tower-fire-85d5cc3f2b36adbc 2026-09-10T13:52:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/maharashtra-fda-raids-11-food-units-in-thane-seizes-materials-worth-rs-20-48-lak-972c412bea901a86 2026-09-10T13:47:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/frazier-life-sciences-nets-1-1b-in-long-running-fund-aimed-at-small-midsize-biot-6cbd4c5bcf9742eb 2026-09-10T13:44:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/adarx-pharmaceuticals-seeks-ipo-on-strong-collaboration-deal-with-abbvie-pending-5dba419255f531e9 2026-09-10T13:41:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/imunon-enters-cooperative-research-and-development-agreement-with-national-cance-9c28ffcdb1c0cf0f 2026-09-10T13:40:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-expands-bayer-lung-cancer-drug-approval-71178ea7131e5c0a 2026-09-10T13:39:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/scenic-biotech-appoints-renowned-neurology-drug-development-leader-dr-judith-wal-b0c70810964568e8 2026-09-10T13:33:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/cullinan-therapeutics-inc-common-stock-cgem-stock-price-news-quote-history-9e08eae6d576bb60 2026-09-10T13:33:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/samsung-biologics-signs-usd-262-million-manufacturing-agreement-with-european-ph-d2defa9f379bb988 2026-09-10T13:32:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/imunon-enters-cooperative-research-and-development-4ff7c827c11dfc18 2026-09-10T13:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/west-pharmaceutical-services-at-wells-fargo-conference-growth-outlook-lifts-7e95f35a8d9d2806 2026-09-10T13:29:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/scynexis-appoints-sanjay-subramanian-cfo-as-biotech-advances-rare-disease-pipeli-7ffff17544555b0f 2026-09-10T13:28:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/major-expansion-of-community-mental-health-support-across-england-a2cb994842375abb 2026-09-10T13:27:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/mrna-cancer-vaccines-biggest-barriers-to-market-5a32cb9618b921d8 2026-09-10T13:26:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/takeda-s-long-serving-r-d-chief-andy-plump-to-retire-in-wake-of-pipeline-success-59af07bbf36e86fb 2026-09-10T13:25:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/burning-rock-biotech-releases-q2-2026-financial-results-8819331f3d074a9a 2026-09-10T13:22:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/update-starton-therapeutics-to-present-at-medinvest-biotech-pharma-conference-d467c5ff3d6873eb 2026-09-10T13:19:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-pre-market-movers-tnon-aeon-surge-coo-cdt-slide-a99c6eadfee151c8 2026-09-10T13:17:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biovie-seeks-fda-meeting-to-plan-phase-3-trial-for-parkinson-s-drug-candidate-4c45ecc8dc428588 2026-09-10T13:16:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/25f1670-gloflon-i-v-catheter-with-injection-valves-wings-20g-1-1-x-33mm-666903112fb8586e 2026-09-10T13:12:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/cannara-biotech-secures-58m-credit-facility-with-bmo-and-td-5c15a8e996887473 2026-09-10T13:07:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/latest-figures-highlight-ongoing-meningitis-b-risk-for-students-d7de382570d1ec44 2026-09-10T13:06:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/burning-rock-q2-revenue-falls-9-3-to-rmb134-7m-cafe7127e11ce51e 2026-09-10T13:04:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-2026-to-2027-46b78a2386536090 2026-09-10T13:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-reports-2026-to-2027-season-32f74fa23fd23c69 2026-09-10T13:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/no-treatment-is-approved-for-menstrual-migraine-abbvie-s-drug-cut-migraine-days-6a69b46a841b8f13 2026-09-10T12:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-extends-migraine-leadership-with-positive-phase-3-atogepant-results-in-me-aa42924a07011e55 2026-09-10T12:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharma-pulse-dhl-s-new-singapore-hub-and-pharma-rethinks-go-to-market-6f1e39d1bd379b78 2026-09-10T12:53:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/geovax-provides-nasdaq-listing-update-and-reaffirms-focus-on-advancing-strategic-e2e455613a5a2210 2026-09-10T12:37:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/unlocking-cell-surface-protein-research-with-site-specific-labelling-4b2c27c5d4f0630d 2026-09-10T12:34:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/oncolytics-biotech-reports-preclinical-pelareorep-activity-maintained-with-ras-i-acb108f11ddc1118 2026-09-10T12:21:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/daesang-expands-into-pharmaceutical-grade-amino-acids-7525345f8975eea5 2026-09-10T12:15:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/an-experimental-cancer-treatment-combination-reduced-tumor-growth-in-early-tests-915d2ac78c60b6c6 2026-09-10T12:15:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/an-investigational-cell-therapy-for-alzheimer-s-and-parkinson-s-will-be-presente-9bd92b46dfeadd3f 2026-09-10T12:05:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-look-at-cleanassure-by-freudenberg-medical-1781dee31e7a4af8 2026-09-10T12:00:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/imn-screws-system-advanced-locking-screw-ec5f499d9db6b051 2026-09-10T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/generic-acetaminophen-by-teva-recalled-because-it-may-contain-foreign-material-7343823d673bcc9f 2026-09-10T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/dxc-500i-clinical-analyzer-and-dxc-500-au-clinical-chemistry-analyzer-0e5e9773dfcba50d 2026-09-10T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/centricity-high-acuity-anesthesia-2ada63128acd97cc 2026-09-10T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/data-on-five-year-remission-with-a-myeloma-treatment-will-be-presented-in-scotla-a31339569a772091 2026-09-10T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-is-biohaven-pharmaceutical-stock-sliding-today-d8352213f625eea5 2026-09-10T11:46:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-booming-business-on-wall-street-would-love-more-biotechs-to-quietly-die-23a99c530fc41a86 2026-09-10T11:46:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/eyepoint-updates-duravyu-phase-3-wet-amd-data-a001c4dce8827879 2026-09-10T11:38:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/cervomed-announces-initial-results-from-the-phase-2a-clinical-trial-of-neflamapi-8e9e18b565ad084e 2026-09-10T11:34:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/3145507-hippokratis-10x20-ply-ref-1020121301-070cc64470b4812d 2026-09-10T11:33:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-hair-brand-vegamour-snapped-up-by-kvd-beauty-owner-belle-brands-9e5b5f7223daebe3 2026-09-10T11:30:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/cervomed-announces-initial-results-from-the-phase-2a-clinical-trial-of-neflamapi-93171a452257b7a9 2026-09-10T11:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/burning-rock-biotech-s-q2-revenue-falls-net-loss-widens-on-central-laboratory-we-3a2bfe5a57b7c6c6 2026-09-10T11:29:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/burning-rock-biotech-reports-second-quarter-2026-financial-results-and-business-3604b6a838f831f6 2026-09-10T11:20:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/prelude-therapeutics-receives-fda-clearance-of-investigational-new-drug-ind-appl-173e26866817c76e 2026-09-10T11:13:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/can-simulation-help-foundation-trainee-pharmacists-prepare-for-prescribing-754b389753a9f647 2026-09-10T11:12:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/migraine-and-acne-included-in-new-prescribing-pharmacy-first-pathways-3ea2469614a56a9c 2026-09-10T11:12:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/uzbekistan-pharmaceutical-output-reaches-uzs-3-5-trillion-in-seven-months-e698870d82152c1b 2026-09-10T11:10:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/phase-1-2-clinical-trial-of-opgx-best1-shows-positive-results-for-inherited-reti-693efb757e3769e0 2026-09-10T11:09:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/podcast-key-readouts-from-esc-and-ers-37928ee094726d75 2026-09-10T11:00:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/new-suicide-risk-research-will-join-five-posters-on-a-treatment-e30968146e5d4bba 2026-09-10T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sk-biopharm-s-in-licensed-epilepsy-drug-opcalim-hits-partial-fda-clinical-hold-58e7c243c85a1a2c 2026-09-10T10:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hhs-appoints-permanent-fda-cber-cder-heads-40d9e998d4d06de3 2026-09-10T10:52:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/spain-pushes-for-access-toolbox-in-eu-biotech-rules-1688a317e36915f9 2026-09-10T10:48:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/inauguration-ceremony-of-the-nafdac-pharmacist-reserve-group-3142b109dbb0e447 2026-09-10T10:45:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-appeals-court-skeptical-of-bid-to-curtail-abortion-pill-access-078244ed36863e9c 2026-09-10T10:40:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/join-the-danish-medicines-agency-s-atmp-open-house-c8681c32f51f75b3 2026-09-10T10:39:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-to-expect-from-uniqure-s-upcoming-huntington-s-gene-therapy-readout-e0aa083eeef3c734 2026-09-10T10:36:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/roivant-is-one-of-the-savviest-dealmakers-in-biotech-it-also-has-a-secret-weapon-c406bfe29c9a43b3 2026-09-10T10:36:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/squarepoint-ops-llc-sells-106-171-shares-of-ultragenyx-pharmaceutical-inc-rare-aaef604b00280d03 2026-09-10T10:16:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-pharmaceutical-industries-prices-4-9-billion-senior-notes-offering-and-anno-b1e8ff5e4e7ab9df 2026-09-10T10:11:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/power-optimization-solution-ends-costly-grid-related-shutdowns-at-major-pharmace-895389c9339efb13 2026-09-10T10:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/active-pharmaceutical-ingredients-market-demand-insights-ee7be79d74ee8b32 2026-09-10T09:46:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/one-assessment-27-countries-how-eu-joint-reviews-work-afdce1a4bab2fa1a 2026-09-10T09:44:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/when-the-er-is-not-an-option-milestone-s-cmo-on-bringing-afib-rate-control-home-e2e99f9bbe1ee809 2026-09-10T09:36:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/takeda-pharmaceutical-co-ltd-takeda-announces-planned-retirement-of-president-of-cc51e8d4bc8214ff 2026-09-10T09:34:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/takeda-pharmaceutical-announces-planned-retirement-of-president-of-research-deve-57aa87713cda8888 2026-09-10T09:34:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/systech-launches-traceiq-0628e750134c6813 2026-09-10T09:33:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-ud-s-star-campus-is-helping-companies-foster-innovation-in-biotech-bfd0e22feb57c6cb 2026-09-10T09:31:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-growth-trust-stands-out-in-a-stronger-biotechnology-sector-0c5fc1ee6f1de77b 2026-09-10T09:24:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/me-therapeutics-stock-faces-downside-pressure-as-biotech-risk-and-preclinical-un-1ec2178796d0ffa0 2026-09-10T09:19:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biocorrx-inc-appoints-former-acting-white-house-drug-policy-director-richard-j-b-f65963320838259a 2026-09-10T09:16:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/yourgene-insight-dpyd-assay-gets-ivdr-accreditation-0f45b3e7e51c89f2 2026-09-10T09:10:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-places-partial-clinical-hold-on-sk-biopharm-s-epilepsy-drug-candidate-opacal-826dea09fcfc58cc 2026-09-10T09:10:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/mog-fda-35ed387f5c4715ce 2026-09-10T09:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/roche-announces-u-s-fda-grants-priority-review-for-enspryng-for-myelin-oligodend-399e802924ad2be2 2026-09-10T09:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/samsung-biologics-signs-350-8-billion-long-term-cmo-deal-with-european-pharmaceu-f69633ea36eaf3ad 2026-09-10T08:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-fluidics-launch-degasi-ng-platform-03359e408ef2f244 2026-09-10T08:47:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/dong-a-socio-holdings-to-rename-itself-dong-a-pharmaceutical-after-otc-merger-811dc3505dca9b48 2026-09-10T08:46:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-fluidics-upgrades-its-degasi-inline-degasser-range-2e8eb202eff2dd75 2026-09-10T08:35:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-evidence-matters-seema-meloni-on-making-data-meaningful-ec1cdcab294170da 2026-09-10T08:33:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/salmonella-outbreak-update-dbba55fa25793323 2026-09-10T08:30:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/mpox-clade-ib-and-clade-iib-outbreak-epidemiological-overview-99d096b3fc6f5884 2026-09-10T08:30:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/salmonella-statistical-releases-5659a2d745797007 2026-09-10T08:30:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/meningococcal-disease-laboratory-confirmed-cases-in-england-2025-to-2026-26816bdfcbfa7f60 2026-09-10T08:30:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/antimicrobial-resistance-awareness-toolkit-for-healthcare-providers-0c0f57c6f41d20ce 2026-09-10T08:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/venture-investor-danish-biotech-innovation-has-caught-up-with-sweden-3b75feb145abd779 2026-09-10T08:20:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-packaging-market-c2e9bc2e819d9a7b 2026-09-10T08:16:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/ebola-disease-caused-by-bundibugyo-virus-democratic-republic-of-the-congo-22eadb56d9fb8544 2026-09-10T08:16:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/gov-healey-eyes-changes-to-life-sciences-programs-as-early-stage-biotechs-strugg-17782bbe9a7546e8 2026-09-10T08:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/scenic-biotech-appoints-renowned-neurology-drug-development-leader-dr-judith-wal-e6c409ade4de9fa6 2026-09-10T07:51:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-6-september-2026-10a6be24e936e540 2026-09-10T07:34:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-quarterly-data-up-820ecbff0a7a966c 2026-09-10T07:29:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-quarterly-data-up-335870a76488db42 2026-09-10T07:28:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-quarterly-data-up-ae1ac0815b2896b3 2026-09-10T07:27:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-quarterly-data-up-bfc75e0710215140 2026-09-10T07:26:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/hhs-names-permanent-leaders-of-fda-drug-and-vaccine-centers-setting-the-directio-a1123af1f2b72c44 2026-09-10T07:19:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/gsk-s-shingrix-recombinant-zoster-vaccine-prefilled-syringe-presentation-approve-0b079b33cbbfd08d 2026-09-10T07:00:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/insilico-medicine-begins-phase-iii-trial-of-ai-discovered-drug-rentosertib-for-i-dadb1e5c66814ac8 2026-09-10T06:46:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/psi-cro-to-present-agile-models-for-emerging-biotech-at-oct-new-england-833dc325de531768 2026-09-10T06:46:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/seismic-pharmaceuticals-enrolls-first-patient-in-phase-3-trial-of-istaroxime-for-2b1bb847cd17d245 2026-09-10T06:46:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/genencell-scandal-revives-korea-s-kosdaq-bio-rout-as-trust-erodes-and-risk-mount-fb54093710b5acb6 2026-09-10T06:31:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/chinese-salmon-by-products-targeted-in-12-8m-biotech-deal-c8108b005d948e22 2026-09-10T05:04:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/u-s-fda-grants-priority-review-for-roche-s-enspryng-for-mogad-an-autoimmune-dise-74fecb34511c53e2 2026-09-10T05:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/stavros-nicolaou-represents-aspen-at-the-9th-annual-sadc-industrialisation-week-07118bf02b625030 2026-09-10T05:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/finnish-aq-biotech-raises-2-5m-to-scale-cancer-screening-in-china-4d00cc33ac6dddf2 2026-09-10T04:29:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/david-hochman-on-the-state-of-medtech-podcast-b55eef03d66537c5 2026-09-10T04:15:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/epidural-kit-correction-medical-action-industries-issues-correction-for-epidural-851483f20d7ce5fa 2026-09-10T04:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/harbour-biomed-advances-long-acting-antibody-candidate-to-phase-3-trial-bb7175ea04a5f45e 2026-09-10T03:42:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/celltrion-wins-approval-to-amend-phase-3-trial-plan-for-darzalex-biosimilar-ct-p-79d50f23bd08e7ef 2026-09-10T03:35:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/kelun-biotech-partner-reports-positive-asthma-phase-2-trial-results-1881334f1adeeee7 2026-09-10T03:34:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/shinsa-english-translation-of-review-report-remede-system-7f6e3ec0b271b2e3 2026-09-10T03:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/kenanga-investment-bank-introduces-world-s-first-hang-seng-biotech-index-structu-2d2c97ee8f163699 2026-09-10T02:54:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/nanjing-zhongchun-biotech-rooted-in-the-ancient-capital-a-reliable-partner-in-fi-f233ef0f32fa8f8a 2026-09-10T02:36:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/aces-alumna-employs-biotech-to-create-sustainable-livestock-production-d26bebab03c30cc8 2026-09-10T02:23:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/sevabertinib-as-a-first-line-targeted-therapy-for-patients-with-her2-mutated-non-b843fcc5b5d08209 2026-09-10T02:21:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/insilico-medicine-doses-first-patient-in-genesis-ipf-3-the-world-s-first-phase-i-e40660aaa25393ab 2026-09-10T00:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gsk-filed-form-6-k-9f35af525cd09cc9 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/green-innovation-gmbh-withdrawal-of-food-additive-petition-animal-use-d90074417ad7c799 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fee-rate-for-using-a-priority-review-voucher-in-fiscal-year-2027-091f27d76fcd85b3 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-2abdf53dea0a6290 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-center-for-advancing-translational-sciences-notice-of-public-online-rou-60eabdf6f3844b70 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medical-devices-cardiovascular-devices-classification-of-the-mechanical-deviatio-e4a18073cc69ba43 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medical-devices-cardiovascular-devices-classification-of-the-temperature-regulat-1550b33975ad5831 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medical-devices-cardiovascular-devices-classification-of-the-extravascular-suppo-cc4f76058ba83528 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medical-devices-clinical-chemistry-and-clinical-toxicology-devices-classificatio-95c9753661159e4c 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medical-devices-ear-nose-and-throat-devices-classification-of-the-cooperative-po-053f86715c0fa357 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medical-devices-gastroenterology-urology-devices-classification-of-the-implanted-19651965512a4fdc 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medical-devices-radiology-devices-classification-of-the-vaginal-hydrogel-packing-cf0bb5f7ee0efe46 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medical-devices-general-hospital-and-personal-use-devices-classification-of-the-e53ed8cdd83debac 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/notice-of-supplemental-funding-medicare-rural-hospital-flexibility-program-bc670a4d8a9047aa 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/announcing-the-intent-to-award-a-single-source-supplement-to-the-senior-medicare-1c16ee7d1b83e6c7 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-caring-for-grandkids-can-help-with-brain-health-4ba5a4d5e5d8579e 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/industry-updates-from-the-field-of-stem-cell-research-and-regenerative-medicine-3a503cfbd5875d78 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/alzheimer-s-prevention-drug-trial-is-a-statin-for-the-brain-on-the-horizon-ee133516c3264597 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/author-correction-colonoscopy-and-fecal-immunochemical-testing-versus-usual-care-a90d22f4b14aa146 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/vanderbilt-integrated-community-tms-for-opioid-recovery-victory-study-protocol-f-535e523f37442b50 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/loberamisal-for-acute-ischemic-stroke-the-lais-randomized-clinical-trial-e300cef805bc32f6 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-trial-barriers-in-neurostimulation-for-pediatric-drug-resistant-epileps-8c28990dc1be1172 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/parenting-process-of-mothers-raising-low-birth-weight-infants-without-medical-te-bb80f8cd84fd4176 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/treatment-effect-discrepancy-between-pfs-and-os-in-antibody-drug-conjugate-trial-f2f94cf97134b20f 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/vancomycin-rescues-sensitivity-to-isoniazid-in-clinical-isolates-of-drug-resista-39ec4e312b3f4baf 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-phase-ii-study-assessing-the-feasibility-and-clinical-efficacy-of-adaptive-imm-81f3d3cf71002166 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-retrospective-analysis-of-clinical-outcomes-following-human-deviations-from-al-60989f4665caf7ce 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/short-term-efficacy-of-tegoprazan-compared-with-esomeprazole-in-patients-with-no-52cea9f1e59c7bc3 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-function-of-angiotensin-converting-enzyme-inhibitors-in-chronic-kidney-disea-8f6ef8fb6d240f67 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/proposals-for-individually-safe-and-realistic-correction-of-antipsychotics-in-ho-05a9f8821c95edf5 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-of-a-rubric-for-assessing-essential-basic-social-skills-required-at-0a0ac5300f3dfbc9 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-evaluation-of-reduced-dose-versus-standard-dose-remdesivir-in-patients-65b51af77de0a252 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/characteristics-of-medication-errors-prevented-by-community-pharmacists-during-t-8fd3fea7f73d36c4 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmacist-secondment-implementation-of-ward-based-pharmaceutical-services-and-c-c92b42fe2d16eb49 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/continuous-intervention-by-an-antimicrobial-stewardship-pharmacist-contributes-t-046de463fe7b026c 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/identification-of-risk-factors-for-lithium-associated-renal-impairment-a-multice-5f41a254316a4f7a 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluation-of-treatment-continuation-and-tolerability-using-the-urine-protein-to-7d9c0f2639c5f082 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/implementation-of-the-electronic-tracing-report-system-and-evaluation-of-its-use-71b92bcdcc397e3b 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/introduction-fcc82029050d3cfc 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/epidemiology-of-acute-kidney-injury-aki-and-sepsis-associated-aki-in-critically-b6d5977523dd237c 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-effect-of-a-telephonic-reminder-on-fasting-duration-in-children-undergoing-c-81dd7d56c74043e5 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-evaluation-of-sternomental-and-hyomental-distance-based-dynamic-airw-9b0a21c89b21e9a8 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/phantom-plethysmography-a-pulse-oximeter-artifact-caused-by-ambient-light-9d789979f52ddb2d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/thoracic-continuous-spinal-anesthesia-for-prolonged-thoracolumbar-fixation-and-k-39160d2fd342c76e 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/morphine-ketamine-combination-for-acute-trauma-analgesia-unanswered-questions-be-a688b64ea7fdcefb 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/therapeutic-responses-and-6-month-clinical-outcomes-in-sarcoidosis-a-longitudina-1dfb2b94343d3422 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-evaluation-of-patient-performed-cleaning-methods-on-the-integrity-of-1841900d0724de48 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-profile-risk-factors-and-treatment-outcomes-of-diabetic-foot-ulcers-a-p-4373b3d863bde44d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/association-between-brain-natriuretic-peptide-and-intradialytic-hypotension-in-h-a365fbb4949ebe9d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/left-atrial-appendage-occlusion-vs-oral-anticoagulants-current-evidence-and-deba-5f809c5eb8e4f23b 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/electrotherapy-in-pediatric-rehabilitation-a-structured-narrative-review-of-clin-d2236a91b304d8e6 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cbct-based-anatomical-assessment-of-lingual-bone-availability-relevant-to-the-me-4d89c9009e1b662a 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/personality-and-coming-to-terms-with-cancer-a-cross-sectional-study-of-five-fact-0ead1686b1643e4b 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/circulating-interleukin-17-across-airway-disease-phenotypes-a-single-center-obse-2fdf11ea2437bca3 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/impact-of-age-on-success-of-3d-printed-cranial-remolding-orthoses-for-deformatio-9aa46e3dc891e64d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/exercise-induced-bronchoconstriction-in-school-aged-children-born-very-preterm-p-ae54f67e30689774 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/multilevel-mechanisms-and-clinical-efficacy-of-psilocybin-in-depression-treatmen-c152eb701a32b92c 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/user-centered-design-approach-to-dynamic-clinical-decision-support-in-primary-pr-311b856abb73970d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comment-on-huang-et-al-accuracy-and-agreement-of-a-45-mg-versus-a-75-mg-13c-urea-c3adf5d3af9f3d93 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-outcomes-and-new-treatments-in-pediatric-brain-tumors-a7ae81bda7df0329 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-mitochondrial-support-to-mitohormetic-readiness-a-micronutrient-centric-ext-f324d9fbecf27cf9 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/impact-of-ethanol-sclerotherapy-on-pelvic-pain-and-quality-of-life-in-patients-w-272a8ec4a97d9120 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparison-of-live-birth-rates-between-calorie-restricted-diet-and-metformin-pri-e6f52d6cd1926e2d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/shunt-pathophysiological-mechanisms-and-clinical-implications-of-ineffective-cir-3955f02cf56865e4 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hypericin-and-hyperforin-from-st-john-s-wort-are-potent-intestinal-ugt-inhibitor-10d289e1efb49df5 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/foxc1-drives-lung-cancer-metastasis-and-functions-as-a-target-for-ai-enabled-ant-1defa9cda85e5e4f 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/beyond-a-negative-trial-timing-molecular-residual-disease-and-antibody-biology-i-bb05374d7dd1fb5e 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/acupuncture-for-chronic-tinnitus-study-protocol-for-a-clinical-trial-with-audito-8863c954452a2b82 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/control-effect-of-dual-mechanism-myopia-control-lenses-on-myopia-in-children-and-7da4cb5525ea95aa 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-warrant-in-medical-llm-evaluation-459f9d52d16df761 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/presidential-inaugural-address-2026-expanding-computer-based-testing-strengtheni-15fe341fe4ecbd79 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/artificial-intelligence-and-the-right-to-a-fair-trial-in-the-context-of-ensuring-b0afc141737b48ad 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/larval-density-development-and-distribution-of-costelytra-giveni-in-a-first-year-dfa5c9918d6a640a 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-contribution-of-instagram-influencers-to-drug-literacy-a-digital-communicati-9b940a97b351f178 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/one-year-comparison-of-three-maintenance-doses-of-vitamin-d3-600-1000-and-2000-i-7d271c298d361625 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-drug-interactions-and-pharmacological-complexity-as-prognostic-determinants-36411921172495c4 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/when-thyrotropin-meets-growth-hormone-clinical-challenges-of-a-mixed-gh-tsh-secr-582838b0171f14b7 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/indications-of-a-dependent-invention-for-the-use-of-which-a-compulsory-license-m-090bbb27c034b7e9 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/integrating-clinical-and-cephalometric-assessment-a-comparative-review-b29ec57ce2d2f40a 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/photodynamic-therapy-of-onychomycosis-modern-photosensitizers-and-clinical-effic-64ce2376748684d7 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/procedural-and-clinical-outcomes-of-second-generation-robotic-assisted-versus-ma-2ff0a102943ed8cd 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cardiac-troponin-in-pediatric-cardiology-toward-standardized-interpretive-framew-c21aedff40641d2d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-comparative-evaluation-of-p-tau217-stability-in-serum-and-plasma-using-two-val-e3b099e3c956cdd5 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/din-spec-91532-a-process-oriented-framework-for-quality-assurance-in-clinical-ma-af7479e9fd68713e 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-factors-related-to-cardiac-conduction-disturbance-in-patients-with-wild-1960f220eca28d40 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-impact-of-hospital-associated-disability-in-patients-with-acute-decompe-5990a34ce35f7358 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/high-intensity-statins-and-the-post-discharge-clinical-outcomes-at-1-year-after-6772e5c513209aca 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/endomyocardial-biopsy-and-clinical-outcomes-in-acute-myocarditis-multicenter-coh-ad26290eeb8a3c67 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/detection-of-crystalline-ibuprofen-components-in-ibuprofen-loaded-sba-15-mesopor-7138db2e1588d3b6 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluation-of-water-related-lt-i-gt-t-lt-i-gt-lt-sub-gt-2-lt-sub-gt-relaxation-b-0d37b85783605e80 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/exploring-the-therapeutic-impact-of-targeting-brk-in-epithelial-derived-cancer-c-de1a23859be6977e 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/realgar-transforming-solution-triggers-ferroptosis-associated-death-in-nb4-leuke-a1c5b8ee91dfa235 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/critical-medicines-lists-in-japan-and-the-european-union-insights-into-supply-re-b3c63434f9bb8e7d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hydrophobic-compounds-in-the-lt-i-gt-paeonia-suffruticosa-lt-i-gt-root-cortex-re-fcc2875b79003b62 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/153abr-clinical-procedure-applications-d0e4148b0fd3773b 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/erratum-safety-tolerability-and-antitumor-activity-of-zipalertinib-among-patient-9348373953769dba 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/erratum-efficacy-and-safety-of-anselamimab-in-immunoglobulin-light-chain-amyloid-94141529a1094132 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/therapy-for-stage-iv-non-small-cell-lung-cancer-with-driver-alterations-asco-liv-959d85f1292c4974 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/reply-to-role-of-risk-reducing-bilateral-mastectomy-in-i-brca1-i-and-i-brca2-i-p-775da0d78d9dcbd0 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/reply-to-olaparib-in-metastatic-breast-cancer-the-impact-of-prior-cyclin-depende-d2c1227aecb440ba 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/intismeran-autogene-plus-pembrolizumab-versus-pembrolizumab-alone-in-high-risk-r-d4126ebab8f61724 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/he-was-always-there-f0fcbcf89c659ca0 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/olaparib-in-metastatic-breast-cancer-the-impact-of-prior-cyclin-dependent-kinase-df42a6f811bc75a6 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/combi-i-long-term-overall-survival-with-spartalizumab-plus-dabrafenib-and-tramet-952659f5b36f2fcf 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/role-of-risk-reducing-bilateral-mastectomy-in-i-brca1-i-and-i-brca2-i-pathogenic-82dafac178eac60b 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/developing-a-histology-based-artificial-intelligence-biomarker-to-predict-adjuva-7a52e5237fb6ed1f 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/should-artificial-intelligence-direct-systemic-therapy-decisions-in-pancreatic-c-c4a0a33b2312faed 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sustaining-high-reliability-amid-artificial-intelligence-adoption-in-oncology-593d81fb37071e65 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/oncology-drug-development-challenges-of-increasingly-available-therapies-ca545af2dd113f6f 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/impact-of-tumor-genomic-profile-on-adjuvant-chemotherapy-efficacy-in-resected-pa-3334b8a840da9cbe 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-and-validation-of-a-computational-histology-artificial-intelligence-ea25f506da3e0dd0 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/phase-ii-clinical-study-of-adebrelimab-and-bevacizumab-combined-with-cisplatin-c-c6e26ef3d70cbaea 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/magrolimab-plus-azacitidine-versus-placebo-plus-azacitidine-in-patients-with-unt-f50f60a602c26239 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/spotlighting-rising-researcher-lucas-attia-from-drug-nanoparticle-engineering-to-80d678c9fb2b6243 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-changes-in-cardiovascular-measures-following-speed-agility-and-quick-7d38e12c591165cb 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/performance-of-artificial-intelligence-chatbots-in-restorative-dentistry-a-compa-9b191fa00532fd63 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sterile-neutrophilic-pseudomembranous-conjunctivitis-associated-with-tisotumab-v-d38695f0b78e7a1b 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparison-of-two-tooth-whitening-treatments-a-randomized-split-mouth-clinical-t-c0c6e1e2d0ef8771 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-observation-on-four-finger-pushing-manipulation-combined-with-acupunctu-a2814a38ddb8384a 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-significance-of-inter-assay-discrepancies-and-regression-derived-correc-3228176469d0ff16 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-clinical-prediction-model-for-self-harm-after-adolescent-traumatic-brain-injur-e24ad5ae8d0cc3dd 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/vancomycin-rescues-sensitivity-to-isoniazid-in-clinical-isolates-of-drug-resista-e8b7cbd1c4a03064 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/when-tests-don-t-fit-the-rules-regulatory-challenges-for-agnostic-metagenomic-ne-331f129d805b783b 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/indications-techniques-and-complications-associated-with-pterygoid-implants-a-sy-83a100367b3cf247 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/diagnostic-yield-of-brain-mri-in-pediatric-short-stature-hypothalamic-pituitary-74fd0b47c4324c38 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-development-and-initial-validation-of-the-perinatal-intrusions-interpretatio-e0c5c555f7035197 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-influence-of-social-media-on-users-intention-to-participate-in-clinical-tria-e5c75968b8839648 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/price-gouging-in-the-b2b-pharmaceutical-market-a-systematic-review-of-unethical-c525db114cfe942a 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hypnosis-for-postoperative-pain-management-following-colectomies-a-single-center-2399ea4259a39d8e 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/heart-failure-among-people-with-hiv-prescription-of-guideline-directed-medical-t-13740b1e548b1bb9 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-user-centric-patient-educational-intervention-in-clinical-practice-helping-wom-65d17fa745ccd8e6 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/autophagy-activation-in-granulosa-cells-as-a-mechanism-of-astaxanthin-action-evi-837d5d6cedcc31a1 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/silk-sericin-fibroin-composite-drug-delivery-systems-for-lung-cancer-mechanistic-8a8fa26cb15838c7 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effects-of-guided-imagery-supported-psychoeducation-on-self-esteem-perceived-str-081b38975cbead8e 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/applying-natural-language-processing-to-address-healthcare-bias-using-care-sd-to-ef4b247727690352 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/when-fear-became-the-barrier-to-care-lessons-of-a-clinical-rapid-response-during-40975bffd5c0cbd9 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-virtual-reality-cardiopulmonary-bypass-simulator-versus-conventional-halstedia-ac64a873d60ef83c 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-lipid-ingestion-is-sensed-the-mechanisms-underlying-intestinal-hormone-secre-22afd06b3217a312 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/differential-detection-of-tau-aggregation-species-using-a-small-molecule-probe-f-d66e0f055a747884 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pre-treatment-prediction-of-ebv-dna-status-in-nasopharyngeal-carcinoma-using-ce-a68cbee4efda910c 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/integrating-artificial-intelligence-and-quantum-chemistry-for-sustainable-pharma-2d6f3ac18e807696 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/author-correction-colonoscopy-and-fecal-immunochemical-testing-versus-usual-care-55d47fa59cf1d06d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/aptamer-functionalized-dna-frameworks-as-targeted-drug-buffers-for-concentration-80b9dd9403406b46 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/an-explainable-ai-framework-for-early-mental-health-screening-and-clinical-decis-d1bcabc444546af5 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/trust-and-the-reliability-of-ai-algorithms-for-clinical-decision-making-support-9e4b561742c5eac6 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/potenzial-und-herausforderungen-von-large-language-models-in-der-klinischen-ents-aab5af7bbb512e77 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-deubiquitinating-enzyme-regulatory-network-in-malignant-progression-of-breas-1ae6f24cf43a9983 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-laboratory-and-radiological-factors-associated-with-posterior-reversibl-ada55e4fd84835f5 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agreement-between-artificial-intelligence-and-periodontists-in-the-detection-of-19457d539500c908 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/preserving-beta-cell-function-in-children-and-adolescents-with-newly-diagnosed-s-57b94481282b6072 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07813208-ph-all-in-chinese-children-diagnosis-treatment-and-survival-eb09a4a0ca15599d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07812636-tirzepatide-and-levonorgestrel-iud-therapy-for-ein-and-early-stage-e-62fa618027a35796 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07812402-the-effect-of-factors-affecting-bone-mineral-density-measurement-res-2973f03482cf3684 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07812142-retrospective-analysis-of-the-second-year-of-safety-surveillance-of-2d8c760820377312 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07811817-the-outcomes-of-sympathetic-cardiac-denervation-on-postoperative-atr-6898ffb279287097 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07807579-impact-of-dexmedetomidine-versus-propofol-on-intracranial-pressure-i-3ebfbb09eb810a2c 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07802639-treatment-for-asymmetric-crying-facies-6a5482072b6db189 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07796880-neoadjuvant-culmerciclib-combined-with-endocrine-therapy-for-hormone-236a6ff0dd7aaab3 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07757334-trauma-focused-group-therapy-for-adults-with-trauma-related-symptoms-938497b4eae7f668 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07755800-impact-of-an-arginine-containing-toothpaste-on-the-subgingival-micro-a66ba8f161165838 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07619547-longitudinal-immunophenotyping-of-patients-with-inflammatory-bowel-d-3a796411228812d2 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07619014-comparison-of-the-effectiveness-of-miswak-and-manual-toothbrush-in-r-61752a5ba9670351 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07510737-the-effect-of-cross-training-on-clinical-and-functional-outcomes-in-7510d95205e24ef6 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07490925-transpulmonary-pressure-guided-mechanical-ventilation-strategy-in-ri-67a89935b4d97fdb 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07403487-phase-ii-trial-of-rc1416-injection-in-asthma-3a70f1e833dd11d1 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07346768-evaluation-of-anterior-neck-ultrasound-in-predicting-difficult-airwa-e45c6f540528963b 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07301333-a-study-of-single-and-multiple-doses-of-hrs-6257-in-healthy-subjects-b397d0795f6d989a 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07252245-pre-hospital-triage-of-patients-at-intermediate-and-high-risk-for-ac-80a6b5fc1f6fe45d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07195734-testing-the-addition-of-chemotherapy-or-chemo-immunotherapy-to-the-u-eaef4d5ec3a3e699 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07000253-timing-of-comprehensive-local-treatment-after-first-line-systemic-th-342d10d4c9ccc441 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06991751-a-natural-history-of-cardiometabolic-disease-among-us-bhutanese-deve-74080274b3baf1da 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06834984-ritual-synbiotic-a-dietary-supplement-designed-to-impact-gastrointes-812e09906b02af8f 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06728592-emergency-stroke-unit-for-acute-cerebrovascular-events-a-prospective-ce25f2838db0d108 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06687369-a-study-to-compare-pharmacokinetics-efficacy-safety-and-immunogenici-f27ee34c79201243 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06646627-clinical-trial-of-autologous-b7-h3-car-t-cells-in-reoccurent-platinu-64da8d624df467f8 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06595940-genetic-analysis-of-uncommon-disease-presentations-in-non-us-populat-9a7defcdd77feca2 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06485622-outcome-and-improvement-of-different-treatment-in-arteriosclerosis-o-9e6f55f052856edc 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06473857-design-implementation-and-evaluation-of-an-intervention-within-video-e815a59dea39ec4a 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06360822-increasing-equity-in-lung-cancer-screening-b4a214aae70631f2 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06345079-cessation-of-somatostatin-analogues-after-prrt-in-mid-hind-gut-and-p-ed61837c12c16b51 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06339177-hemophagocytic-lymphohistiocytosis-hlh-evaluation-and-research-of-cl-98ebc57a25bf0463 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06277401-exercise-in-patients-with-hypermobile-joints-and-knee-pain-b27705bc9cf79ce5 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06040125-debunking-the-frailty-sarcopenia-adt-axis-in-metastatic-prostate-can-128757a54a83f5c8 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06024746-a-study-to-determine-the-efficacy-and-safety-of-finerenone-and-sglt2-da7f590809573fe2 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06014827-biologically-guided-radiation-therapy-bgrt-and-stereotactic-body-rad-d9c90c38d3384a71 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05960461-families-moving-forward-fmf-connect-pro-for-mental-health-providers-c10658528e77ed2e 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05726526-ckd-specific-telemonitoring-platform-to-minimize-adverse-outcomes-in-6ed1dd4b247198a9 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05713799-trial-of-the-combination-of-alpha-lipoic-acid-and-mirabegron-in-wome-58ca62d5ec6a8459 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05692687-a-post-market-clinical-study-to-evaluate-the-safety-and-performance-d750517fead1c294 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05564390-myelomatch-a-screening-study-to-assign-people-with-myeloid-cancer-to-24330c5ca77ac0cb 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05413343-clinical-study-on-monitoring-the-plasma-concentration-of-ceftazidime-1798b3f69bd38b0f 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05027386-apatinib-mesylate-combined-with-it-regimen-for-the-treatment-of-recu-f8c8487f9f0e5b11 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04864054-gpc3-targeted-t-cell-therapy-ect204-in-adults-with-advanced-hcc-4ac96ef3c3032db6 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04288869-change-in-brain-perfusion-during-induction-of-general-anesthesia-0597049227a260ac 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03964532-talave-induction-talazoparib-followed-by-combination-of-talazoparib-ef82b804574ba6bf 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03952637-a-phase-1-2-study-of-intravenous-gene-transfer-with-an-aav9-vector-e-a43bede94f74abe6 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03424005-a-study-evaluating-the-efficacy-and-safety-of-multiple-treatment-com-7cf230def61e35fe 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03077061-peri-implantitis-reconstructive-surgical-therapy-8ced217a0ad67979 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct01471834-verification-of-the-efficacy-and-safety-of-the-barostim-neo-system-i-92140cd6f7208e5a 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct01426165-effect-of-magnesium-sulfate-infusion-rate-on-magnesium-retention-in-d3fa07dc21a48b44 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct01087320-genome-medical-sequencing-for-gene-discovery-3e5a241c98c3dee8 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct01029873-quilt-2-008-study-of-alt-801-with-cisplatin-in-patients-with-metasta-aa0122aaeeb4afc4 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hanmi-pharmaceutical-target-price-raised-to-650-000-as-roche-deal-value-reflecte-7b981f6d3cd04d61 2026-09-09T23:35:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-rare-after-aspire-miss-and-genglycos-win-has-valuation-3ffec4f293a82118 2026-09-09T23:28:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/portage-biotech-alp-financials-2026-income-statement-and-balance-sheet-alp-a532834d0e460662 2026-09-09T23:15:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/research-national-commission-into-the-regulation-of-ai-in-healthcare-recommendat-ebbddaf59e9d3532 2026-09-09T23:01:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/rebuilding-mexico-s-pharmaceutical-supply-chain-3e5a86b66630a924 2026-09-09T22:42:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/potential-pill-for-peanut-milk-egg-allergies-enters-phase-3-trial-9b77f26228e19997 2026-09-09T22:35:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/louisiana-ag-takes-fda-and-pharmaceutical-companies-to-court-over-abortion-pills-1ec522bb7e31fbae 2026-09-09T21:53:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/louisiana-ag-takes-fda-and-pharmaceutical-companies-to-court-over-abortion-pills-2bbc103d0de45256 2026-09-09T21:46:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/biden-era-by-mail-abortion-pills-can-t-be-halted-despite-safety-data-gap-appeals-e16ccb2f49768bd5 2026-09-09T21:39:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/hhs-names-four-senior-fda-officials-in-leadership-reorganization-54cf11cc363bef01 2026-09-09T21:34:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/generation-park-is-creating-a-national-pharmaceutical-hub-in-houston-bba29ce5588183be 2026-09-09T21:10:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/meet-annalina-che-the-scientist-behind-biotech-start-up-darkfin-labs-c8d101f77eaedcec 2026-09-09T20:08:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/placebos-in-cancer-clinical-trials-what-patients-need-to-know-242a8672b78243ea 2026-09-09T20:06:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/seismic-pharmaceuticals-commences-global-phase-3-trial-of-istaroxime-in-patients-08ecec56915041b8 2026-09-09T20:05:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/shareholders-back-every-proposal-at-purple-biotech-ppbt-2026-meeting-8cc35989e741aa3e 2026-09-09T20:02:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/technology-transfer-success-drivers-and-obstacles-explained-f93565e6205cc9ff 2026-09-09T19:36:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-appeals-court-skeptical-of-bid-to-curtail-abortion-pill-access-b55e1d7b8d59e539 2026-09-09T18:57:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/kelun-biotech-s-twice-yearly-asthma-candidate-skb378-advances-into-phase-iii-6e6421b7f6e08843 2026-09-09T18:54:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/kelun-biotech-s-twice-yearly-asthma-candidate-skb378-advances-into-phase-iii-c198555d2578e70f 2026-09-09T18:35:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-appeals-court-skeptical-of-bid-to-curtail-abortion-pill-access-6e050300f86774f7 2026-09-09T18:31:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/wall-street-slashes-dyne-therapeutics-targets-after-novartis-dm1-trial-failure-f71e254e2955835d 2026-09-09T18:24:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nueva-convocatoria-para-realizar-practicas-preprofesionales-0a0fa80b13f1b170 2026-09-09T18:20:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/u-s-and-tunisian-officials-break-ground-on-renovation-of-ministry-of-health-phar-ba2e86b24a145546 2026-09-09T18:19:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/leukemia-drug-data-suggested-a-different-way-to-treat-diabetes-a-new-biotech-wil-951cf12440ea5591 2026-09-09T17:57:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/cualtos-opens-registration-for-the-bachelor-s-degree-in-pharmaceutical-chemistry-cd37687b38cd07c5 2026-09-09T17:22:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/appeals-court-skeptical-that-louisiana-can-sue-fda-over-mifepristone-being-maile-a16892c426e35ef1 2026-09-09T16:51:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/news-today-satya-niketan-collapse-a-wake-up-call-to-act-but-why-wait-for-tragedi-9e4d71030a910565 2026-09-09T16:37:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharma-s-r-d-commercial-approach-shifts-amid-global-policy-evolution-65d9e6dd72fa76dc 2026-09-09T16:35:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-fluidics-releases-upgraded-degasi-inline-degasser-range-147cc76d79d3987c 2026-09-09T16:32:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-firm-uses-space-to-help-cells-regenerate-bodily-structures-12b843a0aabf818f 2026-09-09T16:21:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-firm-uses-space-to-help-cells-regenerate-bodily-structures-75ef1e4053d689b2 2026-09-09T16:21:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/alpha-genesis-backs-biotech-startups-with-50m-agi-ventures-fund-99f88ef051673c6f 2026-09-09T16:19:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/kura-spins-diabetes-work-into-a-lilly-backed-biotech-startup-ee94fc840173114d 2026-09-09T16:14:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-stocks-to-consider-september-9th-b898d2190cfcaabb 2026-09-09T16:07:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/ima-group-to-showcase-all-in-one-solutions-at-cphi-milan-8f37948273925931 2026-09-09T16:06:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/faq-inside-the-latest-mfn-deals-signed-by-nine-drugmakers-03b08aa8809af0e0 2026-09-09T16:03:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/one-state-s-abortion-ruling-could-affect-all-50-0b0a9758c1ef7862 2026-09-09T16:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/four-biotech-stories-heating-up-right-now-f51da81af50695d6 2026-09-09T15:55:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-fills-four-senior-roles-including-top-officials-for-drugs-vaccines-and-tobac-12068fd76e56966c 2026-09-09T15:55:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-promoting-visiting-impact-assessment-8e5c43f577238ed7 2026-09-09T15:46:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/veraxa-biotech-designates-raju-willener-as-cfo-801ec29de9a56a5a 2026-09-09T15:46:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-medical-device-licensing-regime-impact-assessment-27313ede92bd836d 2026-09-09T15:46:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-050bf26e4894b2ca 2026-09-09T15:46:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-mhra-reforms-impact-assessments-d4da977182c6d068 2026-09-09T15:46:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-changes-to-pharmacy-appeals-process-impact-assessment-a5f9700a9414e0ed 2026-09-09T15:46:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-changes-to-section-75-of-nhs-act-2006-impact-assessment-5f9809bc31c7871f 2026-09-09T15:46:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-patient-safety-measures-impact-assessments-092abe2dadcce996 2026-09-09T15:46:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-role-and-functions-of-the-restructured-dhsc-fact-sheet-89c454d704f2bab3 2026-09-09T15:46:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-structural-measures-to-icbs-and-foundation-trusts-impact-assessments-7a34cf0996abe91d 2026-09-09T15:46:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-providers-fact-sheet-ad8fa072da7a9f6e 2026-09-09T15:46:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-icbs-as-strategic-commissioners-fact-sheet-6de16d25a204e1ef 2026-09-09T15:46:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-abolishing-nhs-england-impact-assessment-00de0de68dc58510 2026-09-09T15:45:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-icbs-as-strategic-commissioners-equality-impact-assessment-61dc9515198e3cd9 2026-09-09T15:45:54.000Z weekly 0.7